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ABSTRACT 
HIF-1α in the Heart:  Provision of Ischemic Cardioprotection and Remodeling of 
Nucleotide Metabolism 
by 
Joe Wu  
 
In our studies we found that stabilized expression of HIF-1α in heart led to better 
recovery of function and less tissue death after 30 minutes of global ischemia, via 
mechanisms that preserve the mitochondrial polarization.  Our group previously showed 
that HIF-1α conferred ischemic tolerance by allowing cardiomyocytes to use fumarate 
as an alternative terminal electron acceptor to sustain anaerobic mitochondrial 
polarization.  The source of fumarate was identified as the purine nucleotide cycle 
(PNC).  Here we discovered that HIF-1α upregulates AMP deaminase 2 (AMPD2), the 
entry point to the PNC.  The combination of glycolysis and the PNC may protect the 
heart's nucleotide resources.  We subsequently examined the effects that HIF-1α exerts 
on nucleotide metabolism in the ischemic heart.  We found that HIF-1α expression 
reduces adenosine accumulation in the ischemic heart.   As ATP is depleted during 
ischemia, AMP accumulates.  Our results suggest that AMP metabolism is shunted 
towards AMPD2 rather than the adenosine producing 5'-nucleotidase pathway.  
Subsequently, we treated hearts with the PNC inhibitor hadacidin followed by 30 
minutes of global ischemia.  Inclusion of hadacidin reduced ATP and adenylate energy 
charge in the hearts.  These findings allow us to propose that activity of the PNC 
prevents the F0F1 ATP synthase from consuming glycolytic ATP in order to maintain 
mitochondrial polarization during ischemia.  Thus, the PNC provides ATP sparing 
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effects and preserves the energy charge in the ischemic heart.  The fact that ATP and 
adenylate energy charge is better preserved during the initial 20 minutes of ischemia in 
HIF-1α expressing hearts is supportive of our observation that HIF-1α upregulates the 
PNC.  HIF-1α also upregulates adenosine deaminase, which degrades adenosine.  The 
limitation of adenosine accumulation may help HIF-1α expressing hearts avoid toxicity 
due to chronic adenosine exposure.  Finally, we found that HIF-1α induces the 
expression of the nucleotide salvage enzyme hypoxanthine phosphoribosyl transferase 
(HPRT).  Upon reperfusion HPRT serves to reincorporate the nucleotide degradation 
product, hypoxanthine, into the adenylate pool and may prevent the production of 
reactive oxygen species.  Collectively, HIF-1α robustly protects the heart from ischemic 
stress and it upregulates several pathways whose cardioprotective role may extend 
beyond the remodeling of nucleotide metabolism. 
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CHAPTER 1 
INTRODUCTION 
 
 Diatomic oxygen (O2) has not always been a major component of the earth's 
atmosphere.  For instance, during the early Proterozoic era O2 content was less than 
10-5 times that found in the present day atmosphere (Pavlov and Kasting 2002).  During 
that time photosynthetic organisms released O2 into the atmosphere as a metabolic 
waste product.  However, the O2 released readily reacted with iron and other organic 
matter (i.e. O2 sinks).  Approximately 2.4 billion years ago the O2 sinks became 
saturated and atmospheric O2 levels began to accumulate to that found in the present 
day atmosphere.  Concurrently, O2 consuming organisms started to evolve.      
 
 In regards to the importance of oxygen in sustaining life of aerobic organisms, 
Semenza has said that "no substance which when withheld causes death faster" 
(Semenza 1998).  This is because O2 is crucial to cellular survival as it is coupled to 
oxidative phosphorylation in order to produce the cell's energy currency, ATP (Figure 
1.1).  Mechanistically, electron pairs can enter the electron transport chain at complex I 
(I, NADH-CoQ reductase) or complex II (II, succinate-CoQ reductase).  Electrons 
proceed to complex III (III, CoQ-cytochrome C reductase) then to complex IV (IV, 
cytochrome C oxidase) (Figure 1.1).  At complexes I, III, and IV, H+ ions are 
translocated into the intermembrane space as electrons proceed down the redox 
gradient.  A total of 10 or 6 H+ are translocated depending on whether NADH or 
succinate is used as the initial electron donor.  4H+ re-enter the mitochondrial matrix to 
power the F0F1 ATP synthase so that production of ATP can occur.  Compared to 
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glycolysis alone, which only generates a net of 2 ATP molecules per glucose, aerobic 
respiration can generate 30 ATP molecules per glucose and is therefore much more 
efficient (Rich 2003).  Given the importance of O2 for survival, an intricate method of 
oxygen sensing and ability to adapt in oxygen poor environments exists.  This is evident 
by the ability of humans to survive altitudes as high as 29,000 feet as in the case of 
Messner and Habeler in their ascend of Mount Everest without oxygen 
supplementation. 
 
Figure 1.1:  O2 is coupled to the synthesis of ATP via oxidative phosphorylation.  Electrons can 
enter the electron transport chain at I (NADH-CoQ reductase) or at II (succinate-CoQ 
reductase).  In either case, 2e- are passed onto III (CoQ-cytochrome C reductase) then onto IV 
(cytochrome C oxidase).  The passing of an electron pair down the electron transport chain 
leads to 10 H+ and 6 H+ that are translocated to the intermembrane space depending on 
whether NADH or succinate is used as the initial donor, respectively.  The translocation of H+ 
into the intermembrane space sets up an electrochemical gradient, which is then used to power 
ATP synthesis.  Adapted from Lodish et al. (2007). 
 
 The cell's adaptive responses to inadequate oxygen supply is mediated by a 
transcription factor known as hypoxia inducible factor-1 (HIF-1).  HIF-1 was identified 
and named by Semenza and Wang in their effort to find the transcription factor binding 
to a 50 nucleotide hypoxia inducible enhancer on the human erythropoietin gene 
(Semenza and Wang 1992).  Later work revealed that HIF-1 is composed of a 120 kDa 
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α subunit (HIF-1α) and a 91-94 kDa β subunit (HIF-1β) (Wang and Semenza 1995).  
Structurally, HIF-1 belongs to the basic helix-loop-helix PAS family of transcription 
factors (Wang et al. 1995). 
 
 While HIF-1β is constitutively expressed in the nucleus (Jiang et al. 1996), the 
cellular level of HIF-1α is tightly regulated by O2.  Under normoxic conditions a family of 
prolyl hydroxylase domain containing enzymes (PHDs) hydroxylate proline residues 
(Bruick and McKnight 2001; Epstein et al. 2001) on HIF-1α's oxygen-dependent 
degradation (ODD) domain.  It has been recognized that these residues are proline 402 
and proline 564 (Ivan et al. 2001; Jaakkola et al. 2001; Yu et al. 2001; Chan et al. 
2005).  Hydroxylation of these proline residues subsequently allows for interaction of 
von Hippel-Lindau (VHL) tumor suppressor with HIF-1α.  Once VHL binds, HIF-1α 
becomes polyubiquintinated and is subsequently directed towards proteasomal 
degradation (Figure 1.2).  The transcriptional activity of HIF-1α is also controlled by 
oxygen.  During normoxia factor inhibiting HIF (FIH) hydroxylates asparagine residue 
803 (Mahon et al. 2001; Hewitson et al. 2002; Lando, Peet, Gorman, et al. 2002).  
Hydroxylation of this asparagine residue prevents the binding of transcriptional 
coactivators CBP/p300 to HIF-1α's c-terminal transactivation domain (Lando, Peet, 
Whelan, et al. 2002).  Upon stabilization HIF-1α translocates into the nucleus and 
dimerizes with the β subunit (Jiang et al. 1996; Chilov et al. 1999) where transcription of 
genes containing the core 5'-RCGTG-3' hypoxic response element occurs (Semenza et 
al. 1996) (Figure 1.3). 
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 Hypoxia inducible factor-1 has been shown to elicit the upregulation of a vast 
array of genes.  An important adaptation mediated by HIF-1 is ATP production in the 
absence of oxidative phosphorylation via glycolysis.  As such, the core hypoxic 
response element has been found in genes encoding various enzymes of the glycolytic 
pathway (Semenza et al. 1996).  HIF-1 also stimulates the expression of glucose 
transporters in order to increase cellular glucose uptake (Hayashi et al. 2004; Baumann 
et al. 2007).  Hypoxia inducible factor overexpression is a common theme observed in 
cancer and is associated with VHL deficiency in renal cell carcinoma (Maxwell et al. 
1999; Zhong et al. 1999).  Therefore, it was not surprising that German physiologist Otto 
Warburg observed that cancer cells readily produce ATP through glycolysis rather than 
oxidative phosphorylation even in the presence of oxygen.  This phenomenon was 
rightfully named the "Warburg effect" (Warburg 1956).  Semenza has recently found 
that HIF-1α drives the Warburg effect in cancer (Semenza 2007).  Besides the induction 
of glycolysis HIF-1 also upregulates genes that promote oxygen delivery to the cell.  As 
mentioned previously, HIF-1 is responsible for inducing the expression of erythropoietin, 
which stimulates red blood cell synthesis and an increase in hematocrit (Semenza and 
Wang 1992).  Furthermore, HIF-1 increases the expression of vascular endothelial 
growth factor (VEGF) to promote angiogenesis (Liu et al. 1995; Carmeliet et al. 1998; 
Ryan et al. 1998).  
15 
 
 
Figure 1.2:  HIF-1α protein level and activity is tightly regulated by oxygen.  Hydroxylation of 
proline (Pro) residues 402 and 564 by prolyl hydroxylase (PHD) allows von Hippel-Lindau (VHL) 
factor to recognize and bind to HIF-1α's oxygen dependent degradation domain (ODD).  
Subsequently HIF-1α is ubiquitinated and directed towards proteasomal degradation.  Under 
normoxic conditions HIF-1α transcriptional activity is also suppressed.  Factor inhibiting HIF 
(FIH) hydroxylates asparagine (Asn) residue 803, thus preventing the binding of transcriptional 
co-activators CBP/p300 at HIF-1α's c-terminal transactivation domain (cTAD).  Adapted and 
modified from Semenza (2004). 
 
 
Figure 1.3:  Decline in O2 during hypoxia suppresses the activity of PHDs and FIH, thus 
stabilizing and activating HIF-1α.  O2 is a cofactor that is needed for the enzymatic activity of 
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PHDs and FIH.  When O2 level declines, PHDs and FIH activity is abrogated thus stabilizing and 
activating HIF-1α.  HIF-1α translocates into the nucleus, dimerizes with HIF-1β to initiate the 
transcription of genes containing the core 5'-RCGTG-3' hypoxia response element (HRE).  
Adapted and modified from Semenza (2004). 
 
 O2 delivery to the heart tissue is diminished during ischemia.  It is now 
recognized that HIF-1α may play a central role in cardioprotection during ischemic 
stress.  Ischemic preconditioning is a phenomenon whereby exposure of hearts to short 
sublethal durations of ischemia-reperfusion is able to provide protection from further 
damage upon exposure to subsequent longer and lethal episodes of ischemic stress.   
Following a preconditioning protocol consisting of 4 rounds of 5 minutes of ischemia/5 
minutes of reperfusion an increase in HIF-1α protein levels was observed (Eckle et al. 
2008).   In mouse models with a null allele of the HIF-1α locus a loss of preconditioning 
protection in heart was noted (Cai et al. 2003; Cai et al. 2008).  Also, repression of HIF-
1α via siRNA was found to attenuate ischemic preconditioning protection (Eckle et al. 
2008).  Ockaili et al. and Poynter et al. demonstrated that the use of pharmacologic 
inhibitors of prolyl hydroxylase to induce HIF-1α also confers cardioprotection (Ockaili et 
al. 2005; Poynter et al.).  Similarly, administration of siRNA which silences prolyl 
hydroxylase or knockout of prolyl hydroxylases to stabilize HIF-1α have proven to be 
cardioprotective (Natarajan et al. 2006; Hyvarinen et al.).  A drawback to studies using 
PHD inhibitors or knockout is that prolyl hydroxylases mediates pathways in addition to 
HIF-1α (Cummins et al. 2006; Elvidge et al. 2006).  As a result ischemic 
cardioprotection provided by PHD inhibition cannot be solely attributed to HIF-1α 
expression.  Nevertheless, recent findings strongly indicate a prominent role for HIF-1α 
in cardioprotection during ischemia. 
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 As previously mentioned, HIF-1α is degraded in the presence of oxygen.  In 
order to assess the direct effects that HIF-1α expression exerts on the heart, we used a 
mouse model containing a cardiac-specific and doxycycline regulated HIF-1α transgene 
that is mutated to be stable and active in the presence of oxygen, thus circumventing 
the oxygen mediated degradation and suppression of HIF-1α.  Using this mouse model 
we sought to: 1) establish the cardioprotective role of HIF-1α; 2) identify HIF-1α 
mediated mechanisms that provide ischemic cardioprotection; 3) evaluate the metabolic 
changes in the heart as a result of HIF-1α expression. 
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CHAPTER 2 
 
HIF-1α IN THE HEART:  PROTECTIVE MECHANISMS 
 
This work has been published in Wu et al., American Journal of Physiology, Heart and 
Circulatory Physiology, volume 305 (6), H821-H828, 2013 
 
 
SUMMARY 
 
Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that directs many of the 
cellular responses to hypoxia.  In these studies, we have used a mouse model 
containing a cardiac-specific, oxygen-stabilized, doxycycline (Dox-off) regulated HIF-1α 
transgene to probe the role of HIF-1α in cardioprotection.  Hearts used in these studies 
were derived from wildtype (WT) mice, as well as those maintained on doxycycline to 
suppress the HIF-1α transgene (Non-I) or denied doxycycline to express the HIF-1α 
transgene for 2 days (2D) or 6 days (6D).  Whereas HIF-1α protein is undetectable in 
WT mouse hearts, it is present in heart tissue of Non-I transgenic mice, presumably 
because of leakiness of the promoter construct.  In mice denied doxycycline for 2 or 6 
days, HIF-1α is overexpressed to a much greater extent than Non-I or WT animals, as 
expected.  WT and HIF-1α expressing hearts (Non-I, 2D and 6D induced) were 
subjected to 30 minutes of ischemia, and functional recovery was measured upon 
reperfusion.  Recovery of pre-ischemic left ventricular developed pressure was 14% for 
WT, 67% for Non-I hearts, 64% for 2D, and 62% for 6D hearts.  6D hearts have 
increased pre-ischemic glycogen reserves, higher glycogen synthase protein levels, and 
significantly higher lactic acid release during ischemia.  6D HIF hearts were also better 
able to maintain ATP levels during ischemia compared with WT and Non-I hearts. 
Interestingly, Non-I hearts showed no significant increase in glycogen reserves, 
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glycolytic flux, or greater ATP preservation during ischemia and yet were protected to a 
similar extent as the 6D hearts.  Finally, the mitochondrial membrane potential of 
isolated adult myocytes was monitored during anoxia or treatments with cyanide and 2-
deoxyglucose.  HIF-1α expression was shown to protect mitochondrial polarization 
during both stress treatments. Taken together, these data indicate that, while HIF-1α 
expression in heart does induce increases in compensatory glycolytic capacity, these 
changes are not necessarily required for cardioprotection, at least in this model of 
ischemic stress. 
 
INTRODUCTION 
 
 Hypoxia-inducible factor-1α (HIF-1α) is a master regulatory transcription factor 
that directs the cellular response to hypoxia.  When in vivo oxygen tension is sufficient, 
HIF-1α is hydroxylated at proline residues 402 and 564 by a family of prolyl hydroxylase 
domain-containing proteins (PHDs1–3) (2, 27).  Hydroxylation of HIF-1α results in its 
recognition by von Hippel-Lindau factor and its subsequent degradation via proteasomal 
pathways.  Hydroxylation of asparagine residue 803 (Asn803) by factor-inhibiting HIF 
provides an additional regulatory mechanism for HIF-1α (10, 13).  The hydroxylation of 
Asn803 blocks the binding of coactivators CBP/p300 to the C-terminal activating domain 
of HIF-1α, thereby limiting its transcriptional activity.  Thus, HIF-1α is both stabilized and 
its transcription activity is increased through these mechanisms when oxygen tension 
drops.  The present studies are designed to establish if HIF-1α is sufficient to confer 
protection to the heart against ischemia-reperfusion injury and to begin to explore the 
mechanisms through which this protection is afforded.  In pursuit of these aims, we 
used a transgenic mouse model containing a HIF-1α cDNA with alanine substitutions at 
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Pro402, Pro564, and Asn803 as described by Bekeredjian et al. (1).  These 
substitutions result in a HIF-1α protein, termed HIF-1α-PPN, that is stable and displays 
full transcriptional activity in normoxic conditions.  A tetracycline-regulated construct 
was used to obtain regulation of transgene expression.  In the presence of doxycycline, 
transgene transcriptional expression is suppressed and induced when doxycycline is 
excluded from the diet.  The expression of the tetracycline transactivator protein is 
driven by a cardiac-specific myosin heavy chain promoter, thus limiting HIF-1α 
transgene expression to the cardiac myocytes in these animals. 
 HIF-1α was identified in kidney cells as the transcriptional inducer of the 
erythropoietin gene (23, 24, 30).  Subsequently, HIF-1α has been found to be 
ubiquitously expressed and to regulate hundreds of genes involved in metabolism, 
angiogenesis, and stress survival.  One can view the changes directed by HIF-1α as 
compensatory adaptations to an oxygen-deficient environment.  For instance, HIF-1α 
induces the expression of multiple glycolytic enzymes, including glucose transporter 1, 
aldolase A, enolase 1, lactate dehydrogenase, phosphofructokinase, and 
phosphoglycerate kinase (26).  This upregulation of glycolysis decreases the cell's 
reliance on oxidative phosphorylation for ATP.  Most studies on HIF-1α have been 
performed in cancer models, either cell lines or tumor tissue.  Here HIF-1α has been 
found to be a potent promoter of angiogenesis via its upregulation of vascular 
endothelial growth factor and other angiogenic factors (25).  More recently HIF-1α has 
been ascribed the role as the primary driver of the Warburg effect, or the high rates of 
aerobic glycolysis displayed by cancer cells (15).  The close linkage between tumor 
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growth and metastatic potential and the ability to attract vascularization explains the 
intense interest in HIF signaling as it relates to cancer. 
 In heart, much less is known about the role of HIF-1α in pathophysiology. 
Recently, prolonged overexpression of HIF-1α was shown to induce a cardiomyopathy 
that was fully reversible upon cessation of HIF-1α expression.  In the aforementioned 
study, reduced sarco(endo)plasmic reticulum Ca2+-ATPase expression was linked to the 
contractile dysfunction that was observed (1).  In another study, cardiomyocytes treated 
with prolyl hydroxylase inhibitors to induce HIF-1α reduce ATP turnover by 85%, with 
the majority of these energy savings derived from attenuation of calcium 
handling/contractile activities (29).  These findings indicate that HIF-1α may be an 
important driver of the dysfunction observed in ischemic heart disease.  On the other 
hand, evidence has begun to emerge that HIF-1α plays a central role in 
cardioprotection.  Ischemic preconditioning is a phenomenon where exposure of hearts 
to short sublethal durations of ischemia-reperfusion provides protection from further 
damage upon exposure to subsequent longer and normally lethal episodes of ischemic 
stress.  In a mouse model with a null allele of the HIF-1α locus resulting in less 
expression of HIF-1α, a complete loss of preconditioning protection in heart was noted 
(3).  In another recent study, small-interfering RNA (siRNA) repression of HIF-1α was 
found to attenuate preconditioning protection (6).  Several reports have also shown that 
the use of pharmacological prolyl hydroxylase inhibitors to induce HIF-1α levels confers 
cardioprotection in several disparate cardiac model systems (19, 22, 28, 31).  Similarly, 
administration of siRNA, which targets PHD2 (16) or genetic models where PHD2 is 
ablated, proves cardioprotective (17).  Because PHDs have targets in addition to HIF-
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1α, such as Iκkinase-1 (5), studies where PHD is inhibited do not necessarily prove HIF-
1α involvement.  Nonetheless, taken together, these recent findings strongly indicate a 
prominent role for HIF-1α in preconditioning and cardioprotection.  Less clear are the 
HIF-1α-induced mechanisms that are important in providing protection from ischemia-
reperfusion injury in heart.  In these studies, we compare the ischemic stress tolerance 
of hearts that are induced to express HIF-1α-PPN in varying amounts and durations to 
begin to probe the aforementioned questions. 
EXPERIMENTAL PROCEDURES 
 Reagents:  Sterile oxyrase was purchased from Oxyrase (Mansfield, OH). 
Tetramethylrhodamine (TMRM) was purchased from Life Technologies (Grand Island, 
NY).  2,3,5-Triphenyl-2H-tetrazolium chloride (TTC) was obtained from Tokyo Kasei 
Kogyo (Tokyo, Japan).  Rabbit polyclonal primary antibody against HIF-1α was obtained 
from Novus Biologicals (Littleton, CO), whereas rabbit monoclonal primary antibody 
against glycogen synthase was obtained from Cell Signaling (Danvers, MA).  Goat anti-
rabbit secondary antibodies were purchased from Millipore (Billerica, MA) and Cell 
Signaling.  Doxycycline hydrochloride was purchased from RPI (Mount Prospect, IL). 
 Animal model:  B6C3F1 mice containing the HIF-1α-PPN transgene have been 
previously described by Bekeredjian et al. (1).  All mice used were males between 2 and 
3.5 months of age and were routinely maintained on a 625 mg/kg doxycycline-replete 
diet (Harlan Research Laboratories, Madison, WI).  In experiments requiring 2 days of 
HIF-1α expression (2D), mice were switched from doxycycline food to doxycycline-
replete water containing 73 mM sucrose (Mallinckrodt Baker, Phillsburg, NJ) and 0.416 
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mM doxycycline hydrochloride for 2 days followed by maintenance of mice on regular 
food and water for two additional days.  In experiments requiring 6 days of HIF-1α 
expression (6D), mice were maintained on doxycycline-free food and water for 5–7 days 
before experimentation.  Wildtype (WT) B6C3F1 mice were obtained from Harlan.  
Animals were handled in accordance to a protocol reviewed and approved by the East 
Tennessee State University Committee on Animal Care. 
 Isolation of cardiomyocytes from adult mice:  Myocytes from adult mice hearts 
were isolated according to procedures described by O'Connell et al. (18).  Isolated 
myocytes were suspended in 10 ml of plating medium with 25 µM blebbistatin and 
incubated on plates that were precoated with matrigel (BD Biosciences, Rockville, MD) 
diluted 1:40 in DMEM-F-12 (GIBCO, Grand Island, NY) for 1 hour in 5% CO2.  After 
incubation in plating medium, myocytes were maintained on culture medium with 25 µM 
blebbistatin.  Experiments using adult mice cardiomyocytes were performed on the 
same day as cell isolation. 
 Preparation of mice heart homogenates:  Hearts from wildtype (WT), non-
induced (Non-I), 2D, and 6D mice were excised and washed briefly in PBS to remove 
excess blood.  Hearts were then immediately clamped with a set of tongs that were pre-
chilled in liquid nitrogen.  They were then ground into a fine powder using a mortar and 
pestle under liquid nitrogen.  The powdered heart tissue was homogenized in RIPA 
buffer composed of 50 mM TrisHCl, pH 7.4 (Calbiochem, Darmstadt, Germany), 1% v/v 
Triton X-100 (Fisher, Pittsburgh, PA), 1% w/v sodium deoxycholate (Fisher), 0.1% w/v 
SDS (EMD, Billerica, MA), and 1 mM EDTA (Fisher) with 1:40 protease inhibitor cocktail 
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mix (Sigma, St. Louis, MO).  The homogenates were centrifuged at 12,000 g at 4°C for 
10 minutes.  The supernatant was collected.  Protein concentration for the supernatant 
was determined using the Pierce BCA protein assay kit from Thermoscientific 
(Rockford, IL) according to the manufacturer's protocol. 
 SDS-PAGE and western blot:  HIF-1α and glycogen synthase expression were 
evaluated using standard SDS-PAGE and Western blotting techniques.  Protein 
samples were separated using SDS-PAGE in Pierce Tris-HEPES-SDS 4–20% precast 
polyacrylamide gels (Thermoscientific).  Proteins were transferred to polyvinylidene 
difluoride membranes (BioRad, Richmond, CA) at 75 volts for 2 hours.  After transfer, 
Ponceau S (Sigma) staining was used to ensure complete transfer and equal protein 
loading.  Membranes were blocked in 5% nonfat dry milk in TBS with 0.1% Tween 20 
(TBS-T) for 1 hour at room temperature.  HIF-1α expression was probed using a rabbit 
polyclonal primary antibody diluted 1:500 in TBS-T, and glycogen synthase expression 
was probed with a rabbit monoclonal primary antibody at 1:1,000 dilution in TBS-T.  
Both membranes were incubated at 4°C overnight and washed for 5 minutes in TBS-T 
(5x) before incubation with goat anti-rabbit horseradish peroxidase-conjugated (HRP) 
secondary antibody.  Protein bands were detected using the Pierce supersignal 
chemiluminescence substrate (Thermoscientific) in the G:Box fluorescence and 
chemiluminescence imaging system (Syngene, Frederick, MD).  Densitometry was 
performed using ImageJ (National Institutes of Health, Bethesda, MD). 
 Langendorff perfusion:  Hearts were retrograde perfused through the aorta with 
Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8 
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NaHCO3, 2.5 CaCl2, and 10.6 glucose.  The buffer was equilibrated with 95% O2 and 
5% CO2 and maintained at 37°C.  A fluid-filled silicon balloon was inserted in the left 
ventricle through the mitral valve for left ventricular developed pressure (LVDP) 
measurement with a pressure transducer (AD Instruments, Dunedin, New Zealand).  
Balloons were fabricated using methods previously published (14).  Hearts were 
allowed to stabilize during a 25 minute baseline period after which, function, tissue 
viability, lactate accumulation, ATP, and ADP levels were evaluated after hearts had 
been subjected to various ischemia-reperfusion protocols.  For measurement of lactate 
production during ischemia, the perfusate during the first 5 minutes of reperfusion was 
collected.  Lactate content was measured colorimetrically (450 nm) in a 96-well plate 
format following instructions from the Biovision lactate assay kit (Biovision, Milpitas, 
CA). 
 Evaluation of tissue viability after ischemia-reperfusion:  After the initial 
stabilization period, hearts were subjected to 30 minutes of ischemia and 60 minutes of 
reperfusion.  At the end of the protocol, the hearts were perfused with 1% TTC and then 
taken off the cannula to incubate for 15 minutes at 37°C.  Afterwards, the hearts were 
sliced transversely, and images of the transverse slices were taken using a Microtek 
film scanner (Microtek International, Hsinchu, Taiwan).  The viable (stained dark 
orange) and non-viable (unstained yellow) sections were analyzed using Adobe 
Photoshop (Adobe Systems, San Jose, CA). 
 Measurement of pre-ischemic glycogen reserves:  For glycogen content, frozen 
powdered heart tissue was transferred to an Eppendorf tube and 500 µl of ddH2O was 
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added.  The samples were immediately boiled for 5 minutes and centrifuged at 13,000 
RPM.  Protein concentration was determined using the Pierce BCA assay kit 
(Thermoscientific).  Glycogen content was measured colorimetrically at 570 nm on a 96-
well plate format following instructions provided with the Biovision glycogen assay kit 
(Biovision). 
 Measurement of nucleotides:  ATP and ADP measurements in hearts subjected 
to ischemia were done using high-performance liquid chromatography (HPLC) following 
a method established by Giannattasio et al. (7).  At the end of the respective perfusion 
protocol (pre-ischemic, 5, 10, 20, or 30 minutes of ischemia; or 30 minutes of ischemia 
followed by 30 minutes of reperfusion), hearts were freeze-clamped and then pulverized 
to a fine powder using a mortar and pestle.  Next, the frozen heart tissue was 
homogenized in 400 µl of 4% perchloric acid (Alfa Aesar, Ward Hill, MA) to extract 
nucleotides. The homogenate was incubated on ice for 20 minutes.  Following 
incubation, the homogenate was centrifuged at 15,000 g for 15 minutes at 4°C.  The 
supernatant containing total nucleotides was collected and stored in −80°C until further 
processing.  The remaining tissue pellet was lyophilized to obtain the dry tissue weight. 
 Before measurement of ATP and ADP on HPLC, the samples containing total 
heart nucleotides were neutralized in a solution consisting of 4/5 volume 2 M KOH 
(Fisher) and 1/5 volume 1 M KH2PO4 (MP Biomedical, Solon, OH).  After neutralization, 
the samples were incubated on ice for 10 minutes and centrifuged for 15 minutes at 
15,000 g at 4°C.  The resulting supernatant was collected and filtered through a 0.22-
µm syringe filter (Millipore). 
27 
 
 HPLC runs were performed using a binary gradient with increasing organic 
strength.  The binary gradient was programmed into the LCsolutions data acquisition 
software (Shimadzu Scientific Instruments, Columbia, MD).  The mobile phases were 
buffer A, which consists of 8 mM tetrabutylammonium hydrogen sulfate (Acros Organic, 
Morris Plains, NJ) and 0.1 M KH2PO4 (MP Biomedical).  Buffer B consists of 8 mM 
tetrabutylammonium hydrogen sulfate (Acros Organic) and 0.1 M KH2PO4 (MP 
Biomedical) with the addition of 30% CH3CN (Fisher).  Both mobile phase buffers were 
pH to 6.  Sample (100 µl) was injected into a 20-µl loop, and peak detection was done 
using the SPD-M20A diode array detector at 254 nm (Shimadzu Scientific Instruments) 
and recorded with the LCsolutions data acquisition software.  The areas of the peaks 
corresponding to ATP and ADP were integrated using the LCsolutions postrun analysis 
program (Shimadzu Scientific Instruments).  Total ATP and ADP content expressed in 
units of µmole was calculated from the respective calibration curves and normalized 
against the amount of dry tissue collected (grams). 
 Measurement of mitochondrial membrane potential during anoxia and metabolic 
inhibition:  Adult mice cardiomyocytes were plated on 50-mm MatTek dishes (MatTek, 
Ashland, MA) and incubated in 1.5 ml of culture medium as described by O'Connell et 
al. (18) with 200 nM TMRM at 37°C and 5% CO2.  After 30 minutes of incubation in 200 
nM TMRM, the culture medium was substituted with 50 nM TMRM in PBS plus 5 mM 
glucose and 10 mM succinate.  Before imaging, a cover slip was placed over the cells, 
and 15 µl of sterile oxyrase were added.  Oxyrase selectively removes oxygen, creating 
depletion of oxygen in the cardiomyocyte's immediate surroundings.  Fluorescent 
imaging was performed on the Zeiss Axio Observer Z1 inverted fluorescent microscope 
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(Zeiss, Gottingen, Germany).  Images for cardiomyocytes from all mice groups were 
captured using the Zeiss AxioCam MRm monochrome digital camera (Zeiss) at t0, the 
time point immediately after culture medium was substituted with PBS plus 5 mM 
glucose, 10 mM succinate, and 50 nM TMRM.  Subsequent images were captured after 
0.5, 1, 1.5, and 2 hours of incubation with oxyrase.  Images were analyzed with the 
Zeiss AxioVision 4.8.2 software. The number of polarized myocytes (i.e., those 
exhibiting TMRM fluorescence) was counted at each time point of oxyrase incubation 
and was expressed as a percent of polarized myocytes prior to anoxia.  For 
measurement of mitochondrial membrane potential during inhibition of oxidative 
phosphorylation and glycolysis, isolated myocytes were incubated with 200 nM TMRM 
in culture medium for 30 minutes.  After this period, culture medium was replaced with 
PBS plus 50 nM TMRM, 2 mM sodium cyanide (Mallinckrodt Baker), and 5 mM 2-
deoxyglucose (2-DG; Acros), and a series of fluorescent images were taken at 0, 15, 
30, 45, and 60 minutes of incubation. The number of polarized rod-shaped cells at each 
incubation time point (i.e., those displaying TMRM fluorescence) was counted and 
expressed as a fraction of polarized cells prior to cyanide and 2-deoxyglucose 
treatment. 
 Statistical analysis:  Data reported here are expressed as means±SEM.  
Statistical analysis was performed using one-way ANOVA followed by Student-
Newman-Keuls post hoc testing using GraphPad Prism 5 (La Jolla, CA). 
RESULTS 
HIF-1α-expressing hearts tolerate ischemia better.  
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 Hearts derived from WT and transgenic animals induced to express HIF-1α for 
the indicated times were retrograde perfused and subjected to 30 minutes of ischemia 
followed by reperfusion to allow recovery.  No differences in the spontaneous beating 
rate or LVDP were noted between HIF-1α-expressing and control hearts before 
ischemia.  Upon cessation of perfusion, the ischemic contracture was found to be more 
slowly developing and of a lower ultimate magnitude in 2D- and 6D-induced HIF-1α 
hearts (Figure 2.1).  Recovery of function following ischemia was remarkably higher in 
Non-I, 2D, and 6D HIF-1α-induced hearts compared with WT hearts (Figure 2.2A).  The 
magnitude of ischemic contracture was significantly lower for 2D-induced and 6D-
induced hearts, but not Non-I hearts, compared with the WT hearts (Figure 2.2B). 
 Next, tissue viability after the ischemic challenge was assessed using TTC 
staining.  Tissue viability was found to correlate well with the enhanced functional 
recovery of the hearts (Figure 2.3, A and B).  Somewhat surprisingly, the recovery of 
pre-ischemic LVDP and tissue viability of HIF-1α-PPN Non-I hearts was equivalent to 
the 2D-induced and 6D-induced hearts (Figures 2.2 and 2.3).  This finding caused us to 
examine the possibility of HIF-1α-PPN “leakage” in the hearts of animals maintained on 
a doxycycline-replete diet.  Indeed, we find that, while Non-I heart extracts contain far 
less HIF-1α protein than their induced counterparts, they do have higher levels than WT 
hearts (Figure 2.3C).  Perhaps this should not have been unexpected given that HIF-1α-
PPN has been modified to be stable under normoxic conditions via the substitution of 
critical amino acids within its degradation domain.  Thus, any small expression leakage 
will result in some accumulation of the stable HIF variant.  The results indicate that, 
while HIF-1α-PPN expression is much lower in the Non-I hearts, it is sufficient to protect 
30 
 
to a similar extent, at least against this stress protocol.  In contrast, the moderation of 
ischemic contracture appeared to require the higher, induced levels of HIF-1α (Figure 
2.2B). 
HIF-1α causes glycogen synthase induction, glycogen accumulation, and 
increased glycolytic flux during ischemia.  
 Because ischemic contracture has been reported to be delayed and reduced in 
magnitude by higher glycogen reserves, we next examined the effects of HIF-1α 
expression on glycogen levels in the HIF-expressing and WT hearts.  Although a trend 
was observed for higher glycogen reserves in all the hearts expressing HIF-1α-PPN, 
only the 6D HIF-induced mouse hearts had significantly higher levels of glycogen stores 
compared with WT and Non-I hearts (Figure 2.4A).  Given the higher glycogen stores at 
the initiation of ischemia, we sought to estimate the glycolytic flux during the 30 minutes 
of no-flow ischemia.  Accordingly, the next experiment measured the lactic acid 
accumulated during the 30 minutes of ischemia that is released during the first 5 
minutes of reperfusion (Figure 2.4B).  As with glycogen stores, lactic acid release was 
significantly elevated in the 6D HIF-induced hearts compared with hearts from WT and 
the Non-I HIF-1α-PPN mice.  Recent reports indicating that glycogen synthase is a HIF-
1α-responsive gene might explain the higher levels of glycogen stores in the HIF-
expressing hearts.  Consistent with this, we find significantly elevated glycogen 
synthase protein levels in HIF-1α-PPN transgenic mice hearts (Figure 2.4C).  
Interestingly, glycogen synthase protein levels are elevated to a similar extent in Non-I 
hearts as those induced for 2 and 6 days.  The discrepancy between glycogen synthase 
and glycogen levels among the experimental groups probably reflects the complex array 
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of factors that ultimately determine tissue glycogen levels.  Nonetheless, these results 
showing that HIF-1α directs induction of glycogen synthase and glycogen accumulation 
in adult heart are important findings.  Given that glycogen granule accumulation is a 
hallmark of the hibernating myocardium (9), it indicates that HIF-1α may be a driver of 
this pathophysiological phenotype. 
The upregulation of glycolytic metabolism does not explain the protection 
afforded by HIF-1α.  
 The well-known ability of HIF-1α to induce many of the enzymes that comprise 
the glycolytic pathway when coupled to elevated glycogen stores suggests an obvious 
avenue to achieve the cardioprotection observed in the HIF-1α-PPN hearts.  
Mobilization of the glucose stores, and enhanced glycolysis and its attendant ATP 
production during stoppage of perfusion, is consistent with the moderation of ischemic 
contracture and increased lactic acid release that we observe in HIF-expressing hearts. 
To address the issue of glycolytically produced ATP moderating the contracture and the 
damage sustained during ischemia, hearts were flash-frozen at intervals during 
ischemia and extracted, and nucleotide contents were measured with HPLC.  Examples 
of HPLC chromatograms showing nucleotides and their metabolites are provided in 
Figure 2.5.  Hearts derived from 2D- and 6D-induced HIF-1α-PPN hearts maintained 
significantly elevated levels of ATP at 20 and 30 minutes of ischemia compared with WT 
control hearts (Figure 2.6A).  Among the experimental groups, only 6D-induced HIF-1α-
PPN hearts maintained significantly elevated ATP:ADP ratio at any time point of 
ischemia (Figure 2.6B).  The comparison of ATP depletion between Non-I HIF-1α-PPN 
and WT hearts showing no differences in the degree of ATP depletion is most 
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interesting given the high degree of ischemic tolerance the Non-I hearts display.  These 
findings call into question the relative importance of the compensatory increases in 
glucose stores and glycolytic enzymes in the protective phenotype of the HIF-1α-PPN 
hearts.  Other mechanisms besides increasing glycolytic flux during ischemia are 
suggested to be employed by HIF-1α to protect the myocardium.  The next series of 
experiments were designed to begin to probe alternative mechanisms of protection. 
 Previously, we found that the ability of mitochondria to maintain polarization 
during simulated ischemia is strongly associated with protection in the heart cell (29). 
Thus, we tested whether isolated adult cardiomyocytes from HIF-1α-PPN hearts also 
display improved mitochondrial function under similar conditions.   Adult cardiomyocytes 
were isolated from WT, Non-I, 2D- and 6D-induced HIF-1α-PPN hearts and subjected to 
anoxia.  Mitochondrial polarization was monitored with TMRM potentiometric dye for 2 
hours under these conditions.  We find that HIF-1α-PPN myocytes maintained 
mitochondrial polarization in significantly greater numbers than WT cells, with 6D-
induced cardiomyocytes performing best, being little affected over the 2 hour period 
(Figure 2.7).  In the next experiment, the dependency of protection on enhanced 
glycolytic flux was directly addressed.  Myocytes derived from WT, Non-I, 2D- and 6D-
induced HIF-1α-PPN hearts were treated with cyanide and 2-DG to block both oxidative 
phosphorylation and glycolysis, and mitochondrial polarization was followed for 1 hour. 
We find that HIF-1α-expressing myocytes are able to maintain mitochondrial membrane 
potential under these conditions to a significantly greater extent than WT myocytes 
(Figure 2.8).  This finding causes us to conclude that the well-known compensatory 
increase in glycolytic capacity that is induced by HIF-1α is not necessary for the 
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ischemic tolerance conferred by HIF-1α and points to the existence of additional 
mechanisms that center on the mitochondrion. 
DISCUSSION 
 Twenty years after its discovery, HIF-1α is well established to play a central role 
in the cellular response to hypoxia; however, much less is known about its 
cardiospecific effects.  In these studies, we show that forced expression of a stabilized 
mutant version of HIF-1α confers robust protection to adult heart in a common ex vivo 
model of ischemia-reperfusion injury.  Given the prominence of ischemic stress in the 
constellation of pathologies grouped under the umbrella of heart disease, it is of great 
interest to understand the mechanisms the cardiomyocyte employs to protect itself 
against hypoxia stress.  Certainly HIF's actions in protecting the myocyte from 
irreversible damage during ischemia can be regarded as beneficial.  On the other hand, 
evidence also exists that ascribes a pathological role to HIF-1α in the context of 
decreased myocardial function during chronic hypoxia such as occurs in ischemic heart 
disease.  Indeed HIF's pathological and protective mechanisms are likely to overlap, in 
that decreased function and lower ATP turnover represent powerful protective 
maneuvers when oxygen becomes limited (11, 12).  In this vein, we should note that 
HIF-1α-PPN induction for up to 6 days did not change the basal contractile 
characteristics (i.e., LVDP when paced, or spontaneous heart rate, data not shown) of 
mice hearts when they were examined ex vivo with Langendorff perfusion. Thus, the 
robust ischemic protection afforded by HIF-1α expression was not accompanied by any 
indication of pathological response in the time frames examined in this study. 
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 The most prominent effect of HIF-1α-PPN expression on the response of the 
perfused heart to 30 minutes of ischemia is an attenuated ischemic contracture. 
Sometimes referred to as “stone heart,” the underlying mechanisms governing 
contracture are not completely understood (8).  Initiation of contracture is closely tied to 
the rate of ATP depletion and exhaustion of internal glycogen stores (8).  It is important 
to note, however, that the severity of ischemic contracture does not correlate with 
myocardial protection or recovery of function in heart.  This is best illustrated by the fact 
that ischemic preconditioning, which is highly protective, shortens the time until onset of 
contracture probably through depletion of glycogen stores.  This has led to the 
suggestion that glycogen and high rates of glycolysis and acidification during ischemia 
are detrimental to cellular recovery.  The degree of severity and length of the ischemic 
insult probably determine whether mobilization of glycogen stores and glycolytic ATP 
production are effectively beneficial or detrimental to tissue viability (4).  For instance, 
with chronic low-flow ischemia, enhanced glycolytic ATP generation greatly improves 
functional outcomes. 
 Recently, muscle glycogen synthase was shown to be a HIF-1α-inducible gene in 
C2C12 skeletal muscle myotubes and several cell lines (21).  Our results show that HIF-
1α elevates glycogen synthase in adult heart cells and leads to glycogen accumulation, 
especially in 6D HIF-1α-induced hearts, where significant elevations of glycogen 
synthase, glycogen, and lactic acid production during ischemia were noted.  Of 
importance, the enhanced glycolysis was reflected in a significant diminishment of ATP 
depletion in the 6D-induced hearts during ischemia.  The finding that HIF-1α is sufficient 
to cause glycogen accumulation in the adult myocardium is also of significance. 
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Glycogen accumulation is a hallmark of hibernating myocardium.  Given previous 
findings that HIF-1α suppresses oxidative phosphorylation (20), ATP turnover, and 
contractile function (29), a strong circumstantial argument can be made that HIF-1α may 
play a large role in directing the hibernating phenotype in heart.  As mentioned above, 
however, we were unable to detect any changes in contractile function or oxidative 
respiration in 6D HIF-induced hearts.  Specifically, LVDP, dP/dt, and O2 consumption 
were measured in WT, Non-I, and 2D- and 6D-induced hearts, whereas pacing was 
increased in 200-beat/minute step increments from 300 to 1,300 beats/minute.  No 
significant changes in these parameters were found between the hearts in any of the 
experimental groups (data not shown).  We are presently uncertain why HIF-1α-
expressing hearts fail to show any evidence of reduced oxidative phosphorylation (29) 
or contractile function (1) noted in other model systems.  Several possible explanations 
are currently being tested but are beyond the scope of these studies, which have 
focused upon the protective effects of HIF-1α-directed changes. 
 In these studies, we have exploited our inducible HIF-1α-PPN transgenic system 
to provide something akin to the dose-response curve, where the influence of HIF-1α is 
absent in the wildtype: < in Non-I << 2D-induced < 6D-induced derived hearts.  This 
pseudo dose-response yielded interesting insights into the biology of the compensatory 
responses elicited by HIF-1α.  We examined pre-ischemic glycogen reserve, glycolytic 
activity, and ATP depletion kinetics during ischemia in WT, Non-I, and 2D- and 6D-
induced mice hearts.  We found that the Non-I HIF-1α-PPN hearts did not show 
significant increases in pre-ischemic glycogen store, glycolytic flux during 30 minutes of 
ischemia, or increased ability to maintain ATP levels during various times of ischemia 
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compared with WT hearts.  Nonetheless, Non-I hearts were protected to the same 
extent as hearts induced to express HIF-1α for 2 and 6 days.  This suggests that, while 
increasing glycogen reserves before, and glycolytic flux during, ischemia clearly 
represent a compensatory response; it may not comprise the primary mechanism of 
protection to the total global ischemia employed in these studies. 
 Similar to these studies, our work examining the cardioprotective mechanisms of 
the O2 sensor in neonatal cardiomyocytes called into question the central importance of 
the induction of glycolytic capacity and glycogen accumulation in protection (28).  In 
previous work, we found that HIF-1α expression, albeit as the result of 
dimethyloxalylglycine treatment rather than genetic manipulation, led a persistent ability 
to maintain mitochondrial polarization during anoxia or cyanide poisoning, even when 
glycolysis was blocked or the reverse mode of ATP synthase was inhibited.  After 
extensive analysis, we ultimately concluded that fumarate was used as an alternate 
terminal electron acceptor to allow electron flux to continue through complex I during 
anoxia or cyanide poisoning (29).  In the studies shown in Figure 2.7 and Figure 2.8 
isolated adult heart cells were tested in vitro to determine whether the protection 
observed in HIF-expressing hearts would translate into stabilized mitochondrial 
polarization during anoxia.  In both anoxic conditions permissive for glycolysis, and in 
conditions where both oxidative phosphorylation and glycolysis are blocked (cyanide 
and 2-DG present), mitochondrial membrane potential was significantly better 
maintained in the HIF-1α-expressing cardiomyocytes.  Taken together, these results 
reveal that HIF-1α can provide ischemic cardioprotection via mechanisms independent 
of compensatory increases in glycolytic flux and ATP preservation.  Studies are 
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underway to quantitatively measure the flux through fumarate respiratory pathways that 
HIF-1α induces. 
 Clearly HIF-1α is initiating a complex multifactorial compensatory program that 
equips the adult cardiomyocyte with remarkable tolerance to hypoxic stress.  The most 
well-known HIF-1α-driven response to hypoxia is the induction of glycolytic pathway 
enzymes (25).  Our data confirm that glycolytic capacity is increased by HIF-1α in adult 
murine cardiomyocytes and that this reserve is tapped during acute ischemia. 
Somewhat surprising, the findings also call into question the central importance of this 
increased glycolytic capacity as the central mechanism leading to the powerful 
protection conferred by HIF-1α in the acute no-flow ischemic protocol that we employ. 
Rather, isolated cell studies implicate mechanisms that preserve mitochondrial function 
during ischemia in the powerful cardioprotection that is observed. 
 
 
 
 
 
 
 
 
 
 
 
38 
 
FIGURES 
 
Figure 2.1:  Response of murine hearts with varying degrees of hypoxia-inducible factor-1α 
(HIF-1α) expression to 30 minutes of ischemia, followed by reperfusion.  Shown are exemplary 
condensed pressure tracings from Langendorff-perfused hearts derived from wildtype (WT) and 
HIF-1α-PPN mice that were not induced (Non-I) and induced to express HIF-1α for 2 days (2D 
induced) or 6 days (6D induced).  Hearts were subjected to 30 minutes of ischemia following 
pre-equilibration for at least 20 minutes, whereupon they were allowed to recover.  In some 
hearts, the left ventricular balloon was deflated during ischemia and reperfusion.  In the example 
shown here, the balloon was allowed to remain inflated so that ischemic contraction could be 
measured.  LVDP, left ventricular developed pressure. 
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Figure 2.2:  Quantification of cardiac functional recovery after ischemia of the experiment shown 
in Figure 2.1. A: recovery of LVDP after 30 minutes of ischemia.  B: ischemic contracture 
expressed as a percent of basal LVDP. *P < 0.05 vs. WT; n = 6–8 hearts. 
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Figure 2.3:  HIF-1α expression limits myocardial ischemic damage.  A: typical 
triphenyltetrazolium chloride (TTC) staining pattern in WT, non-induced, 2D-induced, and 6D-
induced mouse hearts post-ischemic reperfusion insult; note that viable tissue stains a darker 
orange color.  B: viable tissue was determined by TTC staining in perfused hearts following 30 
minutes of ischemia and 60 minutes of reperfusion.  The percent viable tissue was quantified 
using images of transverse sections of heart ventricles and Adobe Photoshop software.  *P < 
0.05 vs. WT.  C: representative Western blot showing HIF-1α protein levels in protein extracts 
from hearts in the indicated treatment groups. 
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Figure 2.4:  Glycogen reserves are increased in HIF-1α-expressing hearts.  A: measurement of 
glycogen content in WT, non-induced, 2D-induced, and 6D-induced mouse hearts (n = 4 
hearts).  B: accumulated lactate was measured in the perfusion buffer effluent collected during 
the initial 5 minutes of reperfusion after 30 minutes of ischemia.  C: Western blot showing 
glycogen synthase protein levels in WT, non-induced, 2D-induced, and 6D-induced mouse heart 
extracts.  D: densitometry analysis of the glycogen synthase protein band intensity from the 
Western blot experiment shown in C (n = 4). *P < 0.05 vs. WT.  #P < 0.05 vs. non-induced. 
 
 
 
 
 
 
 
 
 A 
 
B 
 
C 
 
D 
Figure 2.5:  Examples of HPLC chromatograms showing the content of adenine nucleotides, 
nucleosides, and nucleobases in mouse hearts.
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  A:  pre-ischemic wildtype mouse heart.  
 
 
 
 
B:  
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pre-ischemic 6 day HIF-1α induced (6D) mouse heart.  C:  wildtype mouse heart after 30 
minutes of ischemia.  D:  6 day HIF-1α induced (6D) mouse heart after 30 minutes of ischemia.  
Peaks:  (1) hypoxanthine {RT=5.05 minutes}, (2) xanthine {RT=5.34 minutes}, (3) inosine 
{RT=8.02 minutes}, (4) IMP {RT=8.89 minutes}, (5) adenosine {RT=12.66 minutes}, (6) AMP 
{RT=13.32 minutes}, (7) ADP {RT=18.40 minutes}, (8) ATP {RT=22.49 minutes}.  RT stands for 
retention time for the indicated peak. 
 
 
Figure 2.6:  ATP levels are better maintained during ischemia in hearts where HIF-1α 
expression has been induced.  Hearts were freeze-clamped and extracted at the indicated time 
points of ischemia.  ATP and ADP levels were measured by reverse-phase HPLC (see 
experimental procedures).  A: ATP content in hearts subjected to increasing durations of 
ischemia.  ATP levels are expressed as a percentage of pre-ischemic values within all 
experimental groups.  Pre-ischemic ATP values were 26.4 ± 3.7, 27.7 ± 8.7, 19.4 ± 11.2, and 
21.4 ± 2.4 µmole/g dry tissue in WT, non-induced, 2D-induced, and 6D-induced mouse hearts, 
respectively.  B: the ATP-to-ADP ratio expressed as a percentage of the pre-ischemic values, 
which are 3.3 ± 0.6, 4.5 ± 1.0, 4.8 ± 0.3, and 3.1 ± 0.6 for WT, non-induced, 2D-induced, and 
6D-induced mouse hearts, respectively.  The data represent means±SEM (n = 3–9).  *P < 0.05 
vs. WT. 
44 
 
 
Figure 2.7:  Mitochondrial membrane polarization is better maintained in HIF-1α-expressing 
adult cardiomyocytes during anoxia.  A: typical TMRM fluorescent image of WT, non-induced 
(Non-I), 2 day-induced (2D), and 6 day-induced (6D) mouse heart cardiomyocytes after 0, 0.5, 
1, 1.5, and 2 hours of anoxia.  B: cells with polarized mitochondria relative to the amount before 
anoxia expressed as means±SEM (n = 3–8). *P < 0.05 vs. WT. 
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Figure 2.8:  HIF-1α-expressing cardiomyocytes maintain polarized mitochondria when both 
oxidative phosphorylation and glycolysis is blocked.  A: representative TMRM fluorescent 
images of cardiomyocytes obtained from WT, Non-I, 2D-induced, and 6D-induced mice after 0, 
15, 30, 45, and 60 minutes of cyanide (CN−) and 2-deoxyglucose (2-DG) treatment to block 
oxidative phosphorylation and glycolysis, respectively.  B: number of rod-shaped cells with 
polarized mitochondria relative to the amount prior to cyanide and 2-DG treatment expressed as 
means±SEM (n = 3).  *P < 0.01 vs. WT.   
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CHAPTER 3 
 
HIF-1α IN THE HEART:  EXPRESSION OF PURINE NUCLEOTIDE CYCLE 
ENZYMES 
 
 
SUMMARY 
 
Previous studies have shown that activation of HIF-1α signaling conferred the ability for 
cardiomyocytes to use fumarate as an alternative terminal electron acceptor to sustain 
anoxic mitochondrial electron transport chain (ETC) activity.  Further investigations 
revealed that the source of fumarate was the nucleotide metabolic pathway known as 
the purine nucleotide cycle (PNC).  In those studies, HIF-1α signaling was induced via 
treatment with prolyl hydroxylase (PHD) inhibitor dimethyloxaloylglycine (DMOG).  
However, as PHD activates pathways in addition to HIF-1α, the direct effect of HIF-1α 
on PNC activity cannot be established.  Here, we utilized wildtype mouse hearts and 
hearts in which HIF-1α is overexpressed to establish whether HIF-1α directly induces 
the enzymes in the PNC.  We report that HIF-1α induces the entry point of the PNC, 
AMP deaminase 2 (AMPD2) while not affecting downstream reaction steps 
adenylosuccinate synthetase (ADSS) and adenylosuccinate lyase (ADSL).  During 
ischemia, the inability for glycolysis to meet ATP demands of the heart leads to an 
imbalance between ATP consumption and ATP synthesis.  Thus, ATP in the heart is 
depleted and AMP accumulates.  AMP can be metabolized by AMP deaminase to IMP.  
Subsequent cycling of IMP through the PNC regenerates AMP.  Thus, the PNC acts as 
a conservation pathway for the heart's nucleotide pool.  The induction of glycolysis in 
conjunction with the PNC by HIF-1α may preserve the heart's adenine nucleotide 
resources during ischemic insult.  These considerations provide the motivation for us to 
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pursue a full understanding of how HIF-1α influences nucleotide metabolism in the 
ischemic heart and results will be presented in the next chapter. 
 
INTRODUCTION 
 
 Studies pioneered by Peter Hochachka demonstrated that succinate is a major 
metabolic end product associated with anoxia (3, 4).  Mechanisms leading to succinate 
production via the conversion of succinyl-CoA and reduction of fumarate have been 
proposed by Hochachka  (Figure 3.1) (3).  Studies by Weinberg et al., Hohl et al., and 
Sridharan et al. have demonstrated that in kidney and cardiomyocytes, succinate 
synthesis under anaerobic conditions occurs mainly via fumarate reduction at 
mitochondrial complex II as indicated in Figure 3.1 (5, 10, 12).   
 
 Sridharan et al. demonstrated that activation of the HIF-1α signaling cascade in 
neonatal mice cardiomyocytes, albeit via treatment with prolyl hydroxylase inhibitor 
DMOG, led to enhanced succinate production during anoxia (10).  These studies led to 
the unexpected finding that aspartate transamination as proposed by Hochachka (3) 
was not the source of fumarate used for succinate synthesis.  The source of fumarate 
instead, was the nucleotide metabolic pathway known as the purine nucleotide cycle 
(PNC; see Figure 3.2).  As ATP is depleted during anoxic stress, AMP accumulates.  
The series of reactions in the PNC starts when AMP is converted to IMP by AMP 
deaminase (Figure 3.2).  IMP is subsequently metabolized by adenylosuccinate 
synthetase, an enzyme that uses aspartate as a co-factor to generate S-AMP (Figure 
3.2).  Hochachka observed that anoxia leads to a depletion in cellular aspartate (3).  
From studies conducted by Sridharan et al., it is clear that the decrease in aspartate is 
due to its metabolism by adenylosuccinate synthetase (10).  S-AMP is finally 
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metabolized by adenylosuccinate lyase to produce AMP and fumarate (Figure 3.2).  
Those cardiomyocytes treated with DMOG were able to initiate electron transfer by 
oxidizing NADH at complex I (Figure 3. 2).  The resulting electron is then taken up by 
fumarate at complex II, which acts as the terminal electron acceptor in place of oxygen.  
This mechanism leads to the synthesis of succinate and the continual pumping of H+ 
from the mitochondrial matrix into the intermembrane space, thus allowing DMOG 
treated cardiomyocytes to maintain mitochondrial polarization during anoxia, leading to 
tolerance from anoxic stress (10). 
 
 Results presented in chapter 2 provide evidence that HIF-1α confers in 
cardiomyocytes, the ability to maintain mitochondrial polarization during ischemia.  
Studies conducted by Sridharan et al. demonstrated that HIF-1α may induce PNC 
activity (10).  In those studies performed by Sridharan et al., HIF-1α signaling was 
activated via inhibition of prolyl hydroxylases (10).  Prolyl hydroxylases target pathways 
in addition to HIF-1α (2).  The aim in this portion of our studies is to examine the 
expression of PNC enzymes in wildtype and HIF-1α expressing hearts in order to 
determine whether HIF-1α directly induces the expression level of PNC enzymes.   
 
EXPERIMENTAL PROCEDURES 
 
 AMP deaminase (AMPD) mRNA expression:  RNA was extracted from wildtype 
mouse hearts (Harlan Research Laboratories, Madison, WI) and HIF-1α-PPN Non-I, 2D, 
and 6D mouse hearts using TRIzol reagent (Life Technologies, Carlsbad, CA).  RNA 
concentration as well as integrity were determined using the Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA).  cDNA was synthesized using the Superscript 
III cDNA synthesis kit (Life Technologies).   For each cDNA synthesis reaction, 2 µg of 
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RNA was added to 1.25 µM oligo(dT)20, 50 ng random hexamers, 0.5 mM dNTP mix, 80 
U RNaseOUT, 5 mM DTT, 1.25 mM MgCl2, and 400 U reverse transcriptase in a final 
volume of 40 µl.  The cDNA synthesis reaction was allowed to proceed for 1 hour at 
50oC and then terminated by heating at 70oC for 15 minutes.  Quantitative PCR was 
performed in triplicate for all samples in a 96 well plate format on the CFX96 real-time 
PCR detection system (BioRad Laboratories, Richmond,CA).  40 cycles were carried 
out.  Each reaction consisted of 50 ng cDNA and1.5 µl of Quantitect AMPD2 or 
transferrin primer from Qiagen in 1x SsoFast Evagreen supermix (BioRad Laboratories).  
AMPD2 mRNA expression was normalized to that of reference gene transferrin and 
results were reported as a percent change in gene expression relative to wildtype. 
      
 Protein expression of PNC enzymes:  Protein samples from WT and HIF-1α-PPN 
Non-I, 2D, and 6D mouse hearts were prepared according to methods detailed in 
chapter 2.  AMPD2 was probed using a mouse monoclonal primary antibody diluted 
1:1000 in TBS-T (Abcam, Cambridge, MA).  ADSS was probed using a rabbit polyclonal 
antibody against ADSS diluted 1:1000 in TBS-T (Proteintech Group, Inc., Chicago, IL).  
The membranes were incubated in primary antibody at 4°C overnight.  After incubation 
in primary antibody, the membranes were washed for 5 minutes in TBS-T (5x) before 
incubation with 1:5000 rabbit anti-mouse horseradish peroxidase conjugated secondary 
antibody for AMPD2 (Abcam) or 1:5000 goat anti-rabbit secondary for ADSS (EMD).  
Protein bands were detected using the Pierce supersignal chemiluminescence 
substrate (Thermoscientific) in the G:Box imaging system (Syngene, Frederick, MD).  
Densitometry of the protein band corresponding to AMPD2 or ADSS was obtained using 
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ImageJ (National Institutes of Health, Bethesda, MD) and results were normalized to 
that of wildtype. 
 
 Sample preparation for PNC enzyme activity assays:  Wildtype mouse hearts 
and HIF-1α Non-I, 2D, and 6D mouse hearts were perfused briefly with phosphate 
buffer saline to wash out excess blood.  Hearts were then ground into a fine powder 
over liquid nitrogen and homogenized in a buffer consisting of 0.089M potassium 
phosphate, 0.18M potassium chloride, and 0.1mM dithiothreitol with 1% v/v protease 
inhibitor cocktail.  BCA assay was used to determine the protein concentration of the 
homogenates.    
   
 AMP deaminase activity:  AMP deaminase enzyme activity was assessed using 
a procedure described by Raffin (8).  Homogenates were diluted to a protein 
concentration of 2.5 µg/µl.  400 µl of the 2.5 µg/µl heart homogenate, which 
corresponds to 1 mg of protein, were added to 2 ml of a reaction mixture containing 
(mM):  50 cacodylic acid, 150 KCl, 10 AMP.  A 250 µl aliquot of the reaction was taken 
upon initiation of the reaction (t0) and after 2 hours of incubation at room temperature.  
125 µl of 4% perchloric acid (Alfa Aesar, Ward Hill, MA) was used to extract nucleotides 
from the reaction aliquots and IMP was detected at 254 nm using the high performance 
liquid chromatography procedure described in chapter 2 and quantified using a 
calibration curve.  IMP production was obtained by subtracting the initial (t0) level from 
that detected after 2 hours of incubation.  AMP deaminase specific activity was reported 
as nmoles of IMP produced per minute per mg protein. 
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 ADSS activity:  Homogenates were diluted to a protein concentration of 2 µg/µl in 
substrate free reaction buffer consisting of 27 mM imidazole-HCl, 50 mM potassium 
chloride, 8.3 mM MgCl2, 5 mM KH2PO4, and 0.16 mM DTT (pH 7.2).  250 µl of the 2 
µg/µl homogenate were added to 350 µl of substrate buffer (i.e. substrate free reaction 
buffer plus substrate).  The final concentration of substrates (mM) in 600 µl of reaction 
volume was 0.5 IMP, 0.3 GTP, 16 creatine phosphate, 4 aspartate, and 0.25 mg 
creatine phosphokinase.   The ADSS reaction is powered by hydrolysis of GTP and the 
resulting GDP strongly inhibits this reaction step in the PNC.  As a result, the nucleotide 
triphosphate regenerating system consisting of creatine phosphate and creatine 
phosphokinase was added to the reaction to regenerate GTP.  S-AMP levels, measured 
by HPLC at 268 nm were determined upon initiation of the reaction (t0) and after 30 
minutes (t30) of incubation at 37
oC and quantified using a calibration curve.  S-AMP 
production was calculated by subtracting the initial (t0) S-AMP content from that found 
after 30 minutes (t30) of reaction.  Specific activity of ADSS was expressed as µmoles of 
S-AMP produced per minute per mg protein.    
 
 ADSL activity:  The protein concentration of heart homogenates was diluted to 2 
µg/µl using 50 mM tris (pH 7.4).  250 µg (125 µl) of each sample were added to 175 µl 
of reaction buffer (50 mM tris with 0.25 mM S-AMP).  Immediately after the reaction was 
started (t0), a 125 µl aliquot of sample was taken and nucleotides were extracted with 
62.5 µl of 4% perchloric acid in order to get a basal level of AMP.  The remaining 
sample was allowed to react for 30 minutes (t30) at 37
oC.  After the 30 minute incubation 
period, 125 µl of sample were drawn and nucleotide extraction was again extracted with 
62.5 µl of 4% perchloric acid.  Perchloric acid extracts were adjusted to pH 7 with a 
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buffer consisting of 4/5 volume 2M KOH and 1/5 volume 1M KH2PO4.  AMP in the 
neutralized perchloric acid extracts was determined using reverse phase HPLC at 254 
nm and quantified with its corresponding calibration curve.  AMP production was 
calculated by subtracting the initial (t0) AMP content from that detected after 30 minutes 
(t30) of reaction incubation.  ADSL activity is reported as µmoles of AMP generated per 
minute per mg protein.   
  
 Statistical analysis:  Data reported are expressed as means±SEM.  Statistical 
significance was tested using one-way ANOVA followed by SNK post-hoc test using 
GraphPad Prism 5 (La Jolla, CA).  Where appropriate,  Student's t-test was used to test 
for statistical significance. 
 
RESULTS 
 
 Figure 3.3a shows that mRNA levels of the enzyme regulating entry into the 
purine nucleotide cycle (PNC), AMP deaminase isoform 2 (AMPD2) is upregulated in 
Non-I, 2D, and 6D mouse hearts as compared to wildtype.  It took 6 days of HIF-1α 
induction (6D) however, for AMPD2 protein to accumulate to levels greater than that 
found in wildtype mouse hearts (Figures 3.3b & 3.3c).  In concurrence with the elevated 
protein expression of AMPD2 in the 6D mouse heart extracts, we find that activity of 
AMP deaminase was increased relative to wildtype hearts (Figure 3.3d).  We did not 
observe any changes in protein or activity level of adenylosuccinate synthetase and 
adenylosuccinate lyase between wildtype and HIF-1α expressing (6D) mouse hearts 
(Figures 3.4 & 3.5). 
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DISCUSSION 
 
 The purine nucleotide cycle has been shown to operate in skeletal muscle, 
kidney, brain, liver and heart (1, 6, 7, 9, 11).  Here, we find that the enzyme regulating 
entry into the purine nucleotide cycle, AMP deaminase isoform 2 (AMPD2) is induced 
by HIF-1α.  During ischemia, glycolysis is used to generate ATP.  However, the rate at 
which ATP is produced from glycolysis cannot match the rate of ATP consumption.  
Thus, ATP is depleted and AMP accumulates.  AMP can be metabolized to IMP by 
AMP deaminase.  Metabolism of IMP by subsequent enzymes of the PNC regenerates 
AMP, which can be thought of as a conservation mechanism for the heart's adenine 
nucleotides.  In addition to glycolysis, which supplies ATP, we now know that HIF-1α 
induces AMPD2, the entry point to the PNC.  These two pathways may function to 
enhance the preservation of the heart's adenine nucleotide pool during ischemia.  
Taken together, these results provide the rationale for us to perform a detailed 
investigation on the effect that HIF-1α exerts on nucleotide metabolism in the ischemic 
heart, results of which will be presented in the next chapter. 
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FIGURES 
 
Figure 3.1:  Pathways leading to succinate production during anoxia in diving mammals as 
proposed by Peter Hochachka.  One pathway starts with the conversion of pyruvate to alanine, 
which generates α-ketoglutarate.  α-Ketoglutarate then enters the mitochondria and is converted 
to succinyl-CoA.  In a reaction catalyzed by succinate thiokinase, succinyl-CoA is converted to 
succinate and GTP or ATP is concamittantly produced.  An alternative pathway initiates when 
aspartate becomes transaminated to oxaloacetate.  Malate dehydrogenase then converts 
oxaloacetate to malate, which enters the mitochondria where it is metabolized to fumarate.  
Fumarate then becomes reduced to succinate at complex II.  Adapted from Hochachka et al. (3)   
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Figure 3.2:  The purine nucleotide cycle (PNC).  The PNC starts when AMP is deaminated to 
IMP by AMP deaminase (AMPD).  Subsequently, IMP is converted to S-AMP in a reaction 
catalyzed by adenylosuccinate synthetase (ADSS).  S-AMP is converted back to AMP utilizing 
adenylosuccinate lyase (ADSL).  The ADSL reaction step also produces fumarate, which can be 
used as an alternative terminal electron acceptor in the electron transport chain to maintain 
anaerobic mitochondrial respiration. 
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Figure 3.3:  HIF-1α upregulates the mRNA, protein, and activity of AMP deaminase (AMPD) in 
mouse hearts.  Hearts were obtained from wildtype mice and those in which the HIF-1α-PPN 
transgene was suppressed (Non-I) or allowed to be expressed for 2 days (2D) or 6 days (6D).  
a) AMPD2 gene expression in mouse heart homogenates was examined using qPCR and 
normalized to reference gene transferrin.  Results are expressed as the % change in gene 
expression relative to WT (n=6).  b) Western blot showing AMPD2 protein expression in mouse 
heart homogenates.  c) Quantification of AMPD2 protein levels in mouse heart homogenates 
(n=6-8).  d) AMPD activity assessed by the amount of IMP produced per minute per mg protein 
in a buffer system containing excess AMP (n=5). * P<0.05 versus WT. 
 
 
Figure 3.4:  HIF-1α does not change the protein expression or activity of ADSS in the heart.  
Extracts were obtained from wildtype (WT) mouse hearts and those where the HIF-1α-PPN 
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transgene has been suppressed (Non-I), expressed for 2 days (2D), or expressed for 6 days 
(6D) to examine protein and activity levels of ADSS.  a)  Representative western blot showing 
ADSS expression in adult mouse heart extracts (top); average ADSS protein expression in 
mouse hearts (n=3-5) (bottom).  b)  Average ADSS activity in mouse hearts (n=5). 
 
 
Figure 3.5:  Adenylosuccinate lyase (ADSL) activity is not different in wildtype and HIF-1α 
expressing 6 day (6D) mouse hearts.  Hearts were obtained from wildtype mice and those that 
have been denied doxycycline to express the HIF-1α-PPN transgene for 6 days (6D) and 
activity of adenylosuccinate lyase was examined.  n=3. 
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CHAPTER 4 
 
HIF-1α IN THE HEART:  REMODELING OF NUCLEOTIDE METABOLISM LEADING 
TO ATTENUATION OF ADENOSINE ACCUMULATION DURING ISCHEMIC STRESS 
 
 
SUMMARY 
 
O2 delivery to heart tissue is compromised during ischemia.  As a result, ATP production 
via oxidative phosphorylation becomes inhibited.  While glycolysis can produce ATP 
anaerobically, the rate of ATP synthesis from this process cannot match the rate of ATP 
consumption.  Therefore, ischemia in the heart leads to a net depletion of ATP and the 
nucleotide pool while nucleobases accumulate.  Having identified that HIF-1α 
upregulates AMP deaminase, the entry point to the adenylate conserving purine 
nucleotide cycle (PNC), we sought to examine how HIF-1α influences nucleotide 
metabolism in the ischemic heart.  Here, we found that HIF-1α expression in the heart 
prevents the degradation of nucleotides under the ischemic setting.  As ATP degrades 
during ischemia, AMP accumulates.  AMP can be metabolized to adenosine by 5'-
nucleotidase isoform 1 or the PNC.  Here, we noted that HIF-1α limits adenosine 
accumulation in the ischemic heart, consistent with the shunting of AMP metabolism 
towards the cardioprotective PNC.  Our group previously showed that HIF-1α confers 
ischemic tolerance by allowing cardiomyocytes to use PNC derived fumarate to sustain 
anaerobic mitochondrial respiration.  Upon further examination, we found that HIF-1α 
also upregulates adenosine deaminase, an enzyme that degrades adenosine.  HIF-1α's 
role in reducing adenosine accumulation in the ischemic heart may seem paradoxical 
since adenosine is known to be a cardioprotective molecule.  However, recent evidence 
indicates that chronic exposure to adenosine can cause toxicity.  Therefore, HIF-1α 
expression may allow the heart to circumvent the toxicity caused by chronic adenosine 
64 
 
exposure.  Collectively, we found that HIF-1α not only preserves the hearts adenine 
nucleotide pool, but it also upregulates pathways whose role in cardioprotection may go 
beyond the remodeling of nucleotide metabolism.  
 
INTRODUCTION 
 
 During ischemia, ATP production via oxidative phosphorylation ceases.  
Glycolysis can generate ATP anaerobically, however, the rate of ATP synthesis from 
glycolysis cannot match the rate at which ATP is consumed.  ATP and the heart's 
nucleotide pool becomes rapidly depleted during ischemia (Figure 4.1) (1, 15, 16, 34).  
This results in the formation of non-phosphorylated nucleoside products such as inosine 
and adenosine, which can freely diffuse into the extracellular space, where they are 
further degraded to nucleobases such as hypoxanthine (Figure 4.1).  The loss of 
nucleosides and nucleobases to the extracellular space reduces the amount of 
precursors that are available for re-synthesis of purine nucleotides via the salvage 
pathway.  Thus, this represents a critical route in which the cellular nucleotide pool is 
depleted during ischemic insult.   
 
 Maintenance of the adenine nucleotide pool is of great importance in the 
ischemic heart, as these are the metabolites necessary for ATP production.  The 
synthesis of adenine nucleotides from de novo pathways is very slow and energetically 
expensive (25) and the loss of precursors limits nucleotide resynthesis from salvage 
pathways.  Furthermore, de novo nucleotide synthesis requires glucose-6-phosphate, 
an intermediate in glycolysis (see review by Lunt et al, 2011) (20).  Under the ischemic 
setting, not only is oxygen delivery diminished, but compromised blood flow in the 
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coronary vasculature limits the delivery of nutrients such as glucose, which is 
metabolized by glycolysis to generate glucose-6-phosphate.  As such, the diminished 
glucose delivery to the heart tissue further hinders de novo nucleotide synthesis.  While 
contractile activity is abolished upon the onset of ischemia, the heart still relies on ATP 
to maintain ionic homeostasis.  Hence, mechanisms that help conserve the heart's 
valuable nucleotide resources could prove protective.   
 
    In the previous chapter, we show that the reaction step regulating entry into the 
purine nucleotide cycle (PNC), AMP deaminase isoform 2 (AMPD2) is induced by HIF-
1α.  Activity of the PNC has been demonstrated in isolated cardiomyocytes subjected to 
anoxic stress (13, 14, 33).  Sabina et al. proposed that the PNC acts to conserve the 
cellular adenine nucleotide pool (32).  As ATP is degraded during ischemia, AMP 
accumulates.  The fate of AMP is either metabolism to adenosine by 5'-nucleotidase 
isoform 1 (5'NT-I) or IMP by AMPD2 (Figure 4.1).  Adenosine is uncharged and freely 
diffuses out of the myocyte.  Alternatively, the IMP that is generated by AMP deaminase 
can be utilized by subsequent steps of the PNC to regenerate AMP, thus fulfilling the 
PNC's role in adenine nucleotide conservation.  In addition to glycolysis, we have 
identified another HIF-1α induced pathway that may exert protective effects on the 
heart's nucleotide resources during ischemia.  As such, it became important for us to 
examine in detail, the effects that HIF-1α exerts on nucleotide metabolism in the heart 
during ischemic stress.  
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EXPERIMENTAL PROCEDURES 
 
 Nucleotide metabolism:  Nucleotide metabolism during ischemia was examined 
in WT as well as HIF-1α Non-I, 2D, and 6D mouse hearts.  All hearts were perfused with 
Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8 
NaHCO3, 2.5 CaCl2, and 10.6 glucose on the Langendorff apparatus for 25 minutes to 
allow stabilization.  Following the stabilization period, hearts were subjected to either 5, 
10, 20, or 30 minutes of ischemia, or perfusion for 2.5 minutes with glucose-free Krebs 
buffer containing 5 mM glycolytic inhibitor iodoacetate (Acros Organics, Morris Plains, 
NJ) followed by 20 minutes of ischemia.  After ischemic stress, nucleotides were 
extracted with 400 µl of 4% perchloric acid and were measured with HPLC as detailed 
in chapter 2.  Nucleotides were quantified using their respective calibration curve and 
results were expressed as µmoles of nucleotide per gram dry tissue.  
 
 Protein expression of adenosine deaminase:  Protein samples from mouse 
hearts were prepared according to experimental procedures outlined in chapter 2.  
Adenosine deaminase was probed using a rabbit polyclonal antibody diluted 1:400 in 
TBS-T (Novus Biologicals, Littleton,CO) and incubated overnight with rocking at 4oC.  
After incubation in primary antibody, the membranes were washed 5x5 minutes with 
TBS-T and then incubated with a goat anti-rabbit horseradish peroxidase conjugated 
secondary antibody (EMD) for 1 hour at room temperature.  The band corresponding to 
adenosine deaminase was detected using the Pierce supersignal chemiluminescence 
substrate in the G:BOX imaging system (Syngene, Frederick, MD).  Densitometry of the 
protein band corresponding to adenosine deaminase was done using ImageJ (National 
Institutes of Health, Bethesda, MD) and results were normalized to that of wildtype.    
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 Adenosine deaminase activity:   Activity of adenosine deaminase was 
determined in WT and 6D mouse heart homogenates according to a method developed 
by Hartwick et al (11).  The volume of homogenate corresponding to 250 µg protein was 
added to a reaction mixture containing 0.065F KH2PO4, 0.06F Na2HPO4, and 17.5 mM 
adenosine.  The volume of reaction mixture added to the homogenates was such that 
the final adenosine concentration in the reaction was 3.5 mM.  Half of the reaction was 
immediately taken out to obtain the initial inosine content (t0).  The remaining half of the 
reaction was allowed to incubate at room temperature for 40 minutes.  HPLC was used 
to monitor the amount of product (i.e. inosine) formed during the reaction.  The amount 
of inosine produced during the incubation period is obtained by subtracting the inosine 
content at the start of the reaction (t0) from the inosine content after the 40 minute 
incubation period.  Adenosine deaminase specific activity was expressed as nmoles of 
inosine formed per minute per mg protein.   
 
 Statistical analysis:  Data reported are expressed as means±SEM.  Statistical 
significance was tested using one-way ANOVA followed by SNK post-hoc test using 
GraphPad Prism 5 (La Jolla, CA).  Where appropriate,  Student's t-test was used to test 
for statistical significance. 
 
RESULTS 
 
 Figure 4.2 shows that HIF-1α allows for better preservation of the heart's total 
adenine nucleotide pool (i.e. sum of ATP, ADP, and AMP) during ischemic stress.   
As ATP degrades during ischemia, AMP accumulates.  AMP accumulation was 
hastened in wildtype mouse hearts during ischemia (Figure 4.3).  The accumulation of 
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AMP during ischemia was delayed in the HIF-1α-PPN mouse hearts.  It took 20 minutes 
of ischemic stress for AMP in Non-I and 2D hearts to reach levels equivalent to wildtype 
(Figure 4.3).  After 30 minutes of ischemia, AMP accumulation was equal across the 
heart groups (Figure 4.3).   
 
 AMP that accumulates during ischemia has two fates.  First, AMP can be 
degraded to adenosine via a reaction catalyzed by 5'-nucleotidase (Figure 4.1).  As 
evident by Figure 4.4a, adenosine accumulated readily in wildtype hearts upon 
exposure to ischemic insult.  On the other hand, adenosine accumulation in Non-I and 
2D hearts was delayed and did not match the levels found in wildtype until 30 minutes 
of ischemia have elapsed.  In hearts that have been expressing HIF-1α for 6 days, 
adenosine levels failed to increase even after 30 minutes of ischemia (Figure 4.4a).  
Alternatively, AMP can be metabolized to IMP during ischemia.  The Non-I, 2D, and 6D 
heart accumulated lower levels of IMP as compared to wildtype after 20 and 30 minutes 
of ischemia (Figure 4.4b).     
 
 Figure 4.5a shows that inosine levels during the initial 20 minutes of ischemia 
was lower in 6D hearts as compared to wildtype, Non-I, and 2D hearts.  Nucleoside 
phosphorylase can further metabolize inosine to hypoxanthine, which is further 
degraded to xanthine.  Here, we found that while hypoxanthine and xanthine levels 
increased in the ischemic heart, they were not different in HIF-1α-PPN hearts as 
compared to wildtype at any time point of ischemia (Figures 4.5b & 4.5c).   
 
 In this initial series of studies, we found that expression of HIF-1α for 6 days 
prevented the buildup of adenosine in the ischemic heart.  In chapter 2, we showed that 
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HIF-1α expression for 6 days enhances glycolytic activity and preservation of ATP in the 
heart during ischemia.  Here, we also showed that in hearts where HIF-1α has been 
expressed for 6 days, the accumulation of AMP was lower during the initial 20 minutes 
of ischemia (Figure 4.3).  Thus, the reduction of adenosine accumulation in HIF-1α 
expressing hearts may merely reflect the lower amount of AMP available for metabolism 
by 5'-nucleotidase.   
  
 To test our hypothesis, we perfused hearts with 5 mM of glycolytic inhibitor 
iodoacetate followed by 20 minutes of ischemia.  At the end of this ischemic stress 
protocol, ATP, ADP, and AMP were reduced to similar levels in wildtype and 6D hearts 
(Figure 4.6).  Yet, 6D hearts still failed to accumulate adenosine to levels similar to that 
in wildtype, while IMP level was not different between these two heart groups (Figure 
4.7).  Here, it is crucial to note that inosine, hypoxanthine, and xanthine accumulated to 
higher levels in 6D mouse hearts as compared to wildtype after this ischemic stress 
protocol (Figure 4.7).  Taken together, our results indicate that pathways besides 
glycolysis must be responsible for decreasing the accumulation of adenosine in the 
ischemic 6D hearts.    
 
 An obvious explanation for the attenuation of adenosine in 6D hearts is the 
increased expression of AMP deaminase isoform 2 (AMPD2).  However, we also 
considered the following two factors in our endeavor to identify mechanisms that 
attenuated adenosine levels in the ischemic 6D HIF-1α expressing hearts.  First is the 
observation that less adenine nucleotides were degraded in the 6D hearts during the 
ischemic time course but levels of hypoxanthine and xanthine that accumulated was 
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equivalent to wildtype.  Second, ATP, ADP, and AMP were depleted to the same level 
in wildtype and 6D hearts when glycolysis was blocked prior to ischemia but yet 6D 
hearts were able to accumulate more inosine, hypoxanthine, and xanthine, the 
downstream degradation products of adenosine and IMP (Figure 4.1).  These two 
observations led us to believe that adenosine deaminase was upregulated in 6D hearts, 
thus allowing for more rapid degradation of adenosine (Figure 4.1).  Figure 4.8 shows 
that indeed, protein and activity of adenosine deaminase is induced in the extracts of 6 
day HIF-1α expressing hearts.   
 
DISCUSSION 
 
 In these studies, we find that HIF-1α preserves adenine nucleotides during 
ischemia in the heart.  The accumulation of nucleotide breakdown products required the 
shortest duration of ischemic stress in wildtype mouse hearts.  A delay is observed in 
Non-I and 2D hearts.  The breakdown of adenine nucleotides is slowest in the 6D 
hearts.  These results suggests a pseuo-dose response such that nucleotide depletion 
during ischemia is fastest in wildtype, slower in Non-I and 2D hearts, and slowest in 6D 
hearts. 
 
 Studies where we blocked glycolysis prior to ischemia indicated additional 
mechanisms contribute to the reduction of adenosine accumulation that we have 
observed during ischemia in 6 day HIF-1α expressing hearts.  The first mechanism we 
considered was the reaction catalyzed by adenosine kinase, which converts adenosine 
back to AMP.  However, as ATP is needed as a phosphate donor to adenosine, the 
likelihood that adenosine kinase is functional under ischemic conditions is slim.  Indeed, 
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it has been shown that adenosine kinase activity is suppressed during ischemic stress 
(5, 21, 27). 
  
 Our finding that HIF-1α induces the expression of AMP deaminase isoform 2 
(AMPD2) provides one explanation to our observation that HIF-1α expression reduces 
adenosine accumulation in ischemic heart.  This suggests that AMP metabolism is 
diverted towards the PNC during ischemia in hearts that express HIF-1α, which should 
enhance the production of fumarate.  As our group has shown in the past, HIF-1α allows 
cardiomyocytes to utilize fumarate derived from the PNC to maintain anaerobic 
mitochondrial respiration, thus leading to enhanced ischemic tolerance.  Our 
observation that adenosine accumulation is limited in HIF-1α expressing hearts is 
consistent with the higher activity of the cardioprotective PNC.  Surprisingly, we 
observed that in HIF-1α expressing hearts, IMP did not accumulate to levels higher than 
wildtype hearts during ischemia, even though HIF-1α upregulates AMP deaminase.  
Unlike tetanic activity of skeletal muscle, where IMP accumulation is proportional to the 
amount of ATP degraded (26), IMP has not been detected in ischemic hearts (16).  This 
has led Manfredi to propose that unknown mechanisms are preventing IMP 
accumulation in the heart during ischemia (24).  Taken together, a multitude of factors 
may play a role in determing the levels of IMP in the heart during ischemic stress and 
we hope to identify these in future studies.  
 
 To further identify pathways that contribute to reduced adenosine accumulation 
during ischemia, we focused on our observation that 6D HIF-1α expressing hearts were 
able to achieve equal or higher levels of adenosine breakdown products during 
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ischemia as compared to wildtype mouse hearts.  Consistent with this result, we found 
that adenosine deaminase protein and activity in heart extracts from 6D mice were 
higher than wildtype.  Our results are consistent with work done by Eltzschig, which 
showed that hypoxia induces the mRNA and protein expression of adenosine 
deaminase (7). 
 
 The finding that HIF-1α limits adenosine accumulation contradicts the protective 
role that this metabolite has been ascribed, particularly in the realm of cardioprotection 
(17, 29, 35, 37).  This is achieved through signaling via various isoforms of cell surface 
adenosine receptors (6, 19, 28).  Immune response has been recognized to contribute 
to the adverse effects associated with ischemia (10, 18).  Various studies show that 
adenosine plays a role in suppressing immune cells by inhibiting their transmigration 
through the vasculature and reducing their production of proinflammatory cytokines (3, 
9, 12).  On the other hand, it has been recognized that chronic exposure to adenosine 
causes toxicity.  Blackburn has postulated that toxicity from chronic adenosine exposure 
may arise from receptor downregulation and activation of adenosine receptors on 
surrounding immune cells (2).  Downey's group showed that prolong exposure of 
adenosine receptors to agonist led to abolishment of cardioprotection provided by 
preconditioning (36).  These results are suggestive of receptor downregulation as a 
result of chronic adenosine exposure.  Adenosine has been shown to stimulate mast 
cell degranulation (31).  In addition, adenosine may also be proarrhythmic (8, 23).  
Furthermore, adenosine has been shown to induce fibrosis (4, 22, 30).  Thus, HIF-1α 
may play a role in maintaining the intricate balance between the benefits of adenosine 
signaling and ill-effects associated with chronic adenosine exposure.  Future studies 
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should examine whether adenosine exposure, long-term, triggers maladaptive 
responses during ischemia and whether HIF-1α provides an approach to limit this. 
  
 Collectively, nucleotide metabolism is remodeled by HIF-1α.  These remodeling 
processes result in better preservation of adenine nucleotides during ischemia.  More 
importantly, HIF-1α reduces the amount of adenosine that accumulates in the ischemic 
heart.  This result is consistent with higher activity of the cardioprotective PNC pathway 
and also suggests that HIF-1α expression in the heart may limit the toxicity associated 
with chronic exposure to adenosine. 
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FIGURES 
 
 
Figure 4.1:  Nucleotide degradation pathways in the ischemic heart.  During ischemia, the rate 
of ATP consumption exceeds its synthesis from glycolysis.  As a result, there is a net 
degradation of ATP and the heart's nucleotide pool while the nucleobase hypoxanthine 
accumulates.   PNC = purine nucleotide cycle.  AMPD2 = AMP deaminase isoform 2.  ADSS = 
adenylosuccinate synthetase.  ADSL = adenylosuccinate lyase.  5'NT-1 = 5'-nucleotidase 
isoform 1 (AMP specific).  5'NT-II = 5'-nucleotidase isoform 2 (IMP specific).  HPRT = 
hypoxanthine phosphoribosyl transferase.  HIF induced pathways are denoted by blue arrows.  
Major pathways that have been proposed previously by others are shown in bold black arrows.  
Adapted from Jennings et al. (16). 
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Figure 4.2:  Wildtype mouse hearts are inept at preserving the adenine nucleotide pool during 
ischemia.  Wildtype mouse hearts, hearts not expressing the HIF-1α-PPN transgene (Non-I), 
and hearts made to express the HIF-1α-PPN transgene for 2 days (2D) and 6 days (6D) were 
subjected to the indicated durations of ischemia.  Nucleotides were measured using HPLC and 
the sum of ATP, ADP, and AMP was taken as the total adenine nucleotide pool.  Pre-isch 
denotes pre-ischemia.  * P<0.05 versus wildtype.  # P<0.05 versus 6D.  n=3-9.    
 
Figure 4.3:  AMP levels in ischemic adult mouse hearts.  Hearts were obtained from wildtype 
mice and those in which the HIF-1α-PPN transgene is suppressed (Non-I), expressed for 2 days 
(2D) or 6 days (6D).  AMP levels were measured at the indicated durations of ischemic stress.  
Pre-isch denotes pre-ischemia.  * P<0.05 versus wildtype.  # P<0.05 versus 6D.  n=3-9. 
 
 
Figure 4.4:  HIF-1α reduces the amount of adenosine and IMP that accumulates in the ischemic 
heart.  Wildtype mouse hearts as well as those not expressing the HIF-1α-PPN transgene (Non-
I), expressing the HIF-1α-PPN transgene for 2 days (2D) and 6 days (6D) were subjected to the 
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indicated durations of ischemia and nucleotides were measured with HPLC.  a) Adenosine.  b)  
IMP.  * P<0.05 versus wildtype.  # P<0.05 versus 6D.  n=3-9. 
 
 
Figure 4.5:  Accumulation of inosine, hypoxanthine, and xanthine in mouse hearts subjected to 
total ex vivo ischemic stress.  Hearts were obtained from wildtype mice and those in which the 
HIF-1α-PPN transgene is suppressed (Non-I), expressed for 2 days (2D) or 6 days (6D).  Hearts 
were subjected to the indicated durations of ischemia.  Nucleotides were extracted and 
measured using HPLC.  Pre-isch denotes pre-ischemia.  a) Inosine.  b) Hypoxanthine.  c) 
Xanthine.  * P<0.05 versus wildtype, # P<0.05 versus 6D.  n=3-9. 
 
 
Figure 4.6:  Inhibition of glycolysis reduces post-ischemic content of ATP, ADP, and AMP to 
similar levels in wildtype hearts and those expressing the HIF-1α-PPN transgene for 6 days.  
Hearts were obtained from wildtype mice and those in which the HIF-1α-PPN transgene was 
expressed for 6 days (6D).  Hearts were perfused for 2.5 minutes with 5 mM glycolytic inhibitor 
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iodoacetate then subjected to 20 minutes of ex vivo ischemia.  After ischemic stress, 
nucleotides were extracted and measured using HPLC.  n=4-5. 
 
Figure 4.7:  Inhibition of glycolysis followed by ischemia leads to attenuation of adenosine (Ado) 
accumulation but increases in accumulation of inosine (Ino), hypoxanthine (HX), and xanthine 
(Xan) in hearts expressing the HIF-1α-PPN transgene.  Hearts were obtained from wildtype 
mice and those in which the HIF-1α-PPN transgene was expressed for 6 days (6D).  Hearts 
were perfused for 2.5 minutes with 5 mM glycolytic inhibitor iodoacetate then subjected to 20 
minutes of ex vivo ischemia.  After ischemic stress, nucleotides were extracted and measured 
using HPLC.  * P<0.05 versus wildtype.  n=4-5. 
 
 
Figure 4.8:  HIF-1α expression induces the protein and activity of adenosine deaminase (ADA).  
Heart homogenates were obtained from wildtype mice and those in which the HIF-1α-PPN 
transgene was suppressed (Non-I), expressed for 2 days (2D), or expressed for 6 days (6D).  a)  
Representative Western Blot showing adenosine deaminase expression (top); average 
expression of adenosine deaminase from 4 to 7 mouse hearts (bottom). b)  Adenosine 
deaminase specific activity in homogenates from 5 mouse hearts.  # P<0.05 versus 6D.  * 
P<0.05 versus wildtype.   
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CHAPTER 5 
 
THE PURINE NUCLEOTIDE CYCLE AND ITS EFFECTS ON NUCLEOTIDE 
METABOLISM IN THE ISCHEMIC HEART 
 
 
SUMMARY 
 
We found that HIF-1α reduces the accumulation of adenosine in the ischemic heart.  
This is consistent with the shunting of AMP metabolism towards AMP deaminase, which 
is upregulated by HIF-1α.  AMP deaminase represents the step regulating entry into the 
nucleotide metabolic pathway known as the purine nucleotide cycle (PNC).  To 
establish a better understanding of the role that the PNC plays in the ischemic heart, we 
perfused wildtype and 6 day HIF-1α induced (6D) mouse hearts with 50 µg/ml (0.42 
mM) adenylosuccinate synthetase inhibitor, hadacidin followed by treatment of hearts to 
30 minutes of ex vivo ischemic stress.  We found that inhibition of the PNC led to a 
reduction of ATP, ATP:ADP, and adenylate energy charge in wildtype and 6D hearts 
during ischemia.  The inhibition of adenylosuccinate synthetase by hadacidin should 
decrease the availability of fumarate used to maintain anaerobic mitochondrial 
respiration.  Our studies allow us to propose a new physiological role for the PNC, 
which is that the PNC preserves ATP, ATP:ADP, and adenylate energy charge via the 
provision of fumarate, which is used as an alternative terminal electron acceptor in 
place of O2 to maintain mitochondrial polarization during ischemia.  This prevents the 
reverse mode operation of the F0F1 ATP synthase, which consumes ATP in order to 
maintain the mitochondrial membrane potential during ischemia.  Therefore, the 
induction of the PNC may contribute to the better preservation of energy charge up to 
20 minutes of ischemic stress that we have observed in 6D HIF-1α expressing hearts. 
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INTRODUCTION 
 
 In chapter 2, we showed that HIF-1α upregulates AMP deaminase, the enzyme 
regulating entry into the PNC.  Furthermore, our finding that HIF-1α attenuates 
adenosine accumulation in ischemic hearts is consistent with the induction of AMP 
deaminase.  Studies related to the PNC have for the most part been done on skeletal 
muscle.  On the other hand, knowledge regarding the PNC and its function in the heart 
remains much more elusive.  Unlike skeletal muscle, studies by Taegtmeyer found that 
workload does not affect the activity of the PNC in heart (8).  This led the group to 
discount any significant role for the PNC in the heart.  However, the heart is particularly 
well equipped to maintain its high energy phosphate content as workload is varied (5).  
Therefore, the model system used by Taegtmeyer may not have been able to capture 
the physiological significance of the PNC in the heart (8).  To delineate the role of the 
PNC in the heart, we subjected hearts to ex vivo ischemia, a condition similar to 
exercise in skeletal muscle where ATP becomes readily depleted.  Hearts were 
subjected to 30 minutes of ischemia alone or pre-treatment with hadacidin, which is a 
PNC inhibitor at the step of adenylosuccinate synthetase, followed by exposure to 30 
minutes of ischemic stress.  Nucleotide content in the heart was measured after 
ischemic stress.  Results were compared between wildtype and HIF-1α expressing 
mouse hearts. 
 
EXPERIMENTAL PROCEDURES 
 
 Nucleotide metabolism:  Wildtype mouse hearts and hearts derived from our HIF-
1α-PPN non-induced (Non-I), 2 day induced (2D), and 6 day induced (6D) mice were 
perfused with Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 
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KH2PO4, 24.8 NaHCO3, 2.5 CaCl2, and 10.6 glucose on the Langendorff apparatus for 
25 minutes to allow stabilization.  Following the stabilization period, hearts were either 
subjected to 5, 10, 20, or 30 minutes of ischemia or perfused for 15 minutes with Krebs 
buffer containing 50 µg/ml hadacidin followed by 30 minutes of ischemia.  Hearts were 
freeze clamped and nucleotides were extracted with 400 µl of 4% perchloric acid.  The 
nucleotide extracts were incubated on ice for 20 minutes.  Following incubation, the 
nucleotide extracts were centrifuged at 15,000 g for 15 minutes at 4°C and the 
supernatant containing nucleotides was removed.  The remaining pellet was lyophilized 
in order to obtain the dry weight (grams) of tissue collected.  Nucleotides were 
measured with HPLC and quantified with their respective calibration curve.  Results are 
expressed as µmoles of nucleotide per gram dry tissue. 
 
 Energy status of the heart:  The heart's energy status provides an indication of 
the energy that can be harnessed during ATP hydrolysis that can be used to carry out 
cellular work and is commonly assessed by calculating the ATP:ADP ratio.  The higher 
the ATP:ADP ratio, the more energy is harnessed upon removal of a phosphate group 
from ATP.  However, under conditions when cellular energetics is compromised, AMP 
content is much more easily perturbed compared to the content of ADP (3).  For 
example, AMP:ATP is equal to (ADP:ATP)2 (3).  Thus, a 5 fold increase in ADP:ATP 
leads to a 25 fold amplification in AMP:ATP.  Therefore, AMP is the best suited 
metabolite used to regulate cellular energetics.  In fact, the cell utilizes AMP activated 
protein kinase as a regulator of cellular energetics via modulation of various metabolic 
pathways (4).  Thus, AMP content must be accounted for when quantifying the energy 
status of the cell.  The adenylate energy charge (EC), first proposed by Atkinson (1), is 
85 
 
calculated from the values of the adenine nucleotide pool and is given by Equation 1.  
This parameter is starting to be much more commonly used to describe cellular 
energetics.   EC ranges from 0 to 1 and is approximately 0.8 in a healthy cell.  A higher 
EC indicates that ATP utilization is favored. 
energy charge		
ATP+0.5ADP
ATP+ADP+AMP
     Equation 1 
 
 
 Statistical analysis:  Data reported here are expressed as means±SEM.  
Statistical significance was tested using one way ANOVA with SNK post-hoc test or 
Student's t-test in GraphPad Prism 5 (La Jolla, CA). 
 
RESULTS 
 
 In these studies, we observed that HIF-1α induction for 6 days (6D) provides 
strong preservation of ATP:ADP (Figure 2.5) and adenylate energy charge (Figure 5.1).  
We find that hadacidin treatment prior to ischemia led to a drastic reduction in ATP and 
ADP in both wildtype and 6D mouse hearts (Figure 5.2a and 5.2b).  AMP levels 
increased in both wildtype and 6D hearts when hadacidin was administered prior to 30 
minutes of ischemia (Figure 5.2c).  The changes in adenine nucleotide content resulted 
in a substantial decrease in the heart's ATP:ADP and adenylate energy charge (Figure 
5.3). 
 
 Next, we examined the effect that hadacidin had on nucleotide breakdown 
products adenosine and IMP in the ischemic heart.  While adenosine levels did not 
change in 6D hearts, it more than doubled in hearts from wildtype mice (Figure 5.4a).  
We find that hadacidin had no effect on IMP content in wildtype hearts and 6D hearts 
that were subjected to 30 minutes of ex vivo ischemia (Figure 5.4b).  Adenosine and 
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IMP can both be degraded to inosine, which is then metabolized by nucleoside 
phosphorylase to hypoxanthine.  We noted that levels of these metabolites were 
unaltered when hadacidin was administered prior to the initiation of ischemic stress 
(Figure 5.5). 
 
DISCUSSION 
 
 The purine nucleotide cycle has been postulated to play a role in conserving 
adenine nucleotides.  For instance, AMP deaminase deficiency leads to exercise fatigue 
and poor recovery of the skeletal muscle's adenine nucleotide pool upon termination of 
intense physical activity (6).  Here, we find that inhibiting the PNC with hadacidin prior to 
ischemia did not enhance the decline of the heart's total adenine nucleotide pool or alter 
the accumulation of nucleotide degradation products.  Only changes in the distribution 
of adenine nucleotides were observed, which is reflected as a decrease in ATP, 
ATP:ADP, and adenylate energy charge.  The lowering of energy charge under these 
stress conditions severely limits the heart's ability to perform cellular work.   
 
 The preservation of cellular energy status (i.e. ATP:ADP ratio) is one of the 
previously postulated roles that the PNC plays.  This is brought about by the coupling of 
the adenylate kinase (2 ADP ↔ ATP + AMP) and the AMP deaminase reactions, 
whereby metabolism of AMP by AMP deaminase shifts the equilibrium of adenylate 
kinase towards ATP synthesis, thus preserving the ATP:ADP ratio.  Data obtained from 
this study allows us to propose a novel approach in which the PNC preserves energy 
status.  While fumarate reduction at complex II can support ATP production by the ATP 
synthase, it has been argued persuasively that this mechanism is unlikely to occur both 
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on theoretical and experimental grounds (2).  Inhibition of adenylosuccinate synthetase 
by hadacidin should reduce the fumarate available for maintenance of anaerobic 
mitochondrial respiration.  As such, the F0F1 ATP synthase would act in reverse in order 
to maintain the mitochondrial membrane potential, in the process further depleting ATP.  
Therefore, reducing the heart's ATP, ATP:ADP, and energy charge during ischemic 
stress.  Thus, our novel proposal is that activity of the PNC prevents the reversal of the 
F0F1 ATP synthase in order to maintain the mitochondrial membrane potential, thereby 
preserving the heart's ATP during ischemic stress.  Collectively, we have identified that 
in addition to glycolysis, the PNC is another crucial mechanism that helps maintain the 
heart's adenylate energy charge during ischemia.  The induction of the PNC by HIF-1α 
may contribute to the ability of the HIF-1α expressing (6D) hearts to preserve energy 
charge better than wildtype hearts, at least up to 20 minutes of ischemic stress. 
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FIGURES 
 
 
Figure 5.1:  HIF-1α preserves adenylate energy charge during ischemia.  Hearts from wildtype 
mice and those maintained on doxycycline to suppress the HIF-1α-PPN transgene (Non-I), 
denied doxycycline for 2 days (2D) or 6 days (6D) to express the HIF-1α-PPN transgene for 2 
and 6 days, respectively, were subjected to the indicated durations of ex vivo ischemia and 
nucleotides ATP, ADP, and AMP were measured using HPLC and adenylate energy charge 
was calculated.  Pre-isch = pre-ischemia. * denotes P<0.05 versus wildtype.  # denotes P<0.05 
versus 6D.  n=3-9. 
 
 
Figure 5.2:  Hadacidin treatment prior to ischemic stress further reduces ATP and ADP but 
increases AMP accumulation in the heart.  Hearts were obtained from wildtype mice and those 
denied doxycycline for 6 days (6D) to induce the expression of the HIF-1α-PPN transgene.  
Hearts were subjected to 30 minutes of ex vivo ischemia with or without prior treatment with 
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PNC inhibitor, hadacidin.  After ischemia, nucleotides were extracted from the hearts and 
measured using HPLC.  a) ATP.  b) ADP.  c) AMP.  * P<0.05 versus wildtype of the similar 
treatment group.  § P<0.05 versus hearts without hadacidin treatment.  n=5.  Note that data 
from hearts subjected to 30 minutes of ischemia alone were taken from the ischemic time 
course studies presented in chapter 4. 
 
 
Figure 5.3:  Inhibition of ADSS with hadacidin prior to ischemia drastically decreases the heart's 
ATP:ADP and energy charge during ischemia.  Wildtype and 6D mouse hearts were subjected 
to 30 minutes of ex vivo ischemia with or without prior treatment with PNC inhibitor, hadacidin.  
a) ATP:ADP ratio.  b) Energy charge.  § P<0.05 versus hearts without hadacidin treatment.  
n=5.  Note that data from hearts subjected to 30 minutes of ischemia alone were taken from the 
ischemic time course studies presented in chapter 4. 
 
 
Figure 5.4:  Effects of hadacidin treatment on adenosine and IMP accumulation in ischemic 
mouse hearts.  Hearts were obtained from wildtype mice as well as those denied doxycycline for 
6 days (6D) to induce the expression of the HIF-1α-PPN transgene.  Hearts were subjected to 
30 minutes of ex vivo ischemia with or without prior treatment with PNC inhibitor, hadacidin.  
After ischemia, nucleotides were extracted from the hearts and measured using HPLC.  a) 
Adenosine.  b)  IMP.  * P<0.05 versus wildtype of similar treatment.  § P<0.05 versus hearts 
without hadacidin treatment.  n=5.  Data from hearts subjected to 30 minutes of ischemia alone 
were taken from the ischemic time course studies presented in chapter 4. 
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Figure 5.5:  Hadacidin treatment prior to ischemia did not alter inosine or hypoxanthine content 
in mouse hearts.  Hearts were obtained from wildtype mice and those denied doxycycline for 6 
days (6D) to allow expression of the HIF-1α-PPN transgene.  Hearts were subjected to 30 
minutes of ex vivo ischemia with or without prior treatment with PNC inhibitor, hadacidin.  After 
ischemia, nucleotides were extracted from the hearts and measured using HPLC.  a) Inosine.  
b) Hypoxanthine.  * P<0.05 versus wildtype of similar treatment.  n=5.  Data from hearts 
subjected to 30 minutes of ischemia alone were taken from the ischemic time course studies 
presented in chapter 4. 
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CHAPTER 6 
 
HIF-1α IN THE HEART:  UPREGULATION OF PURINE SALVAGE ENZYME 
HYPOXANTHINE PHOSPHORIBOSYL TRANSFERASE (HPRT) 
 
 
SUMMARY 
 
Ischemia in the heart leads to rapid depletion of the adenine nucleotide pool as well as 
accumulation of nucleotide degradation products such as hypoxanthine.  Hypoxanthine 
can be utilized by the salvage enzyme, hypoxanthine phosphoribosyl transferase 
(HPRT) to resynthesize adenine nucleotides.  Here we report that HPRT mRNA and 
protein are induced by hypoxia inducible factor 1α (HIF-1α) in mouse hearts.  We have 
demonstrated that HIF-1α expression leads to increased hypoxanthine accumulation in 
the ischemic heart.  Thus, suggesting that HIF-1α expression provides hearts with a 
higher capacity to regenerate adenine nucleotides upon recovery from ischemic stress.  
On the other hand, hypoxanthine can be metabolized by xanthine oxidase upon 
reperfusion to xanthine.  This reaction concomitantly generates a burst of reactive 
oxygen species (ROS).  As a result, the induction of HPRT by HIF-1α may serve the 
dual purpose of re-incorporating hypoxanthine back into the nucleotide pool and 
preventing the production of harmful ROS in ischemia-reperfusion.   
 
INTRODUCTION 
 
 During ischemia, the heart's adenine nucleotide pool is readily depleted and 
nucleobases such as hypoxanthine accumulates (2–4).  Hypoxanthine phosphoribosyl 
transferase (HPRT) is an enzyme that plays a role in nucleotide salvage (Figure 6.1).  
This enzyme catalyzes the transfer of the 5-phosphoribosyl group on phosphoribosyl 
pyrophosphate (PRPP) to hypoxanthine, leading to resynthesis of IMP.  
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Adenylosuccinate synthetase (ADSS), an enzyme of the purine nucleotide cycle (PNC) 
can utilize IMP to generate AMP, which replenishes the heart's adenine nucleotides.  
Hypoxanthine can also be degraded to xanthine by xanthine oxidase during reperfusion 
when O2 is reintroduced to the tissue (Figure 6.1).  The reaction catalyzed by xanthine 
oxidase concomitantly generates a burst of reactive oxygen species in the form of H2O2.  
Here, we wanted to determine whether HPRT, an enzyme that can stimulate nucleotide 
resynthesis and compete with xanthine oxidase for hypoxanthine to potentially reduce 
ROS is a HIF-1α induced cardioprotective pathway. 
 
EXPERIMENTAL PROCEDURES 
 
 mRNA expression of HPRT:  The mRNA expression of HPRT in wildtype and 
HIF-1α Non-I, 2D, and 6D mouse hearts was examined using quantitative PCR.  RNA 
extraction and cDNA synthesis was described under experimental procedures in 
chapter 3.  Quantitative PCR was performed in triplicate for all samples in a 96 well 
plate format on a CFX96 real-time PCR detection system (BioRad Laboratories, 
Richmond, CA).  40 cycles were carried out.  Each reaction consisted of 50 ng cDNA 
and 1.5 µl of Quantitect HPRT or transferrin primer from Qiagen in 1x SsoFast 
Evagreen supermix (BioRad Laboratories).  HPRT mRNA expression was normalized to 
that of reference gene transferrin and results were reported as a percent change in 
gene expression relative to WT. 
 
 Protein expression of HPRT:  Hearts were obtained from WT, Non-I, 2D, and 6D 
mice.  Protein sample was prepared according to experimental procedures stated in 
chapter 2.  HPRT was probed using a rabbit polyclonal primary antibody diluted to 1 
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µg/ml in TBS-T (Novus Biologicals, Littleton, CO).  The membranes were incubated at 
4°C overnight.  After incubation in primary antibody, the membranes were washed for 5 
minutes in TBS-T (5x) before incubation with 1:2500 goat anti-rabbit HRP conjugated 
secondary antibody (EMD Millipore, Billerica, MA).  Protein bands were detected using 
the Pierce supersignal chemiluminescence substrate (Thermoscientific) in the G:Box 
imaging system (Syngene, Frederick, MD).  Densitometry of the protein band 
corresponding to HPRT was obtained using ImageJ (National Institutes of Health, 
Bethesda, MD) and results were normalized to that of WT. 
 
 Statistical analysis:  Data are expressed as means±SEM.  One-way ANOVA was 
performed followed by SNK post-hoc test using GraphPad Prism 5 (La Jolla, CA).   
 
RESULTS 
 
 Figure 6.2a shows that HIF-1α induces the mRNA of HPRT.  In concurrence with 
the mRNA levels, we show that HIF-1α also induces the protein expression of HPRT 
(Figure 6.2b). 
 
DISCUSSION 
 
 Here we report that HIF-1α induces the mRNA and protein of nucleotide salvage 
enzyme hypoxanthine phosphoribosyl transferase (HPRT).  We noted in chapter 4 that 
HIF-1α expression enhances the accumulation of hypoxanthine during ischemia.  
Hypoxanthine can either be a good or harmful metabolite.  It can be utilized by HPRT to 
resynthesize adenine nucleotides.  However, it can also be converted by xanthine 
oxidase to xanthine when oxygen is reintroduced during reperfusion.  The metabolism 
of hypoxanthine by xanthine oxidase leads to a burst of ROS production.  It has been 
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demonstrated that oxypurinol, a xanthine oxidase inhibitor reduces ROS and improves 
cardiac function after ischemia-reperfusion stress (5).  Thus, the induction of HPRT by 
HIF-1α may divert hypoxanthine away from xanthine oxidase metabolism, leading to 
attenuation of ROS.  Taken together, the induction of HPRT by HIF-1α may enhance 
the re-assimilation hypoxanthine back into the adenine nucleotide pool and prevent 
production of harmful ROS during ischemia-reperfusion. 
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FIGURES 
 
 
Figure 6.1:  Hypoxanthine phosphoribosyl transferase (HPRT) reaction mechanism.  HPRT 
catalyzes the transfer of the 5-phosphoribosyl group on phosphoribosyl pyrophosphate (PRPP) 
to hypoxanthine to resynthesize IMP.  Adenylosuccinate synthetase, an enzyme of the purine 
nucleotide cycle (PNC) can utilize IMP to regenerate AMP, which replenishes the heart's 
adenine nucleotides.  The availability of O2 during reperfusion allows xanthine oxidase to 
convert hypoxanthine to xanthine, a reaction that also synthesizes a burst of ROS.  Therefore, 
HPRT induction in HIF-1α expressing hearts may also function to minimize ROS production 
during ischemia-reperfusion insult. 
 
 
Figure 6.2:  HIF-1α upregulates the mRNA and protein of hypoxanthine phosphoribosyl 
transferase (HPRT) in mouse hearts.  HPRT mRNA and protein was examined in wildtype (WT) 
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mouse hearts and those where the HIF-1α-PPN transgene was suppressed (Non-I), expressed 
for 2 days (2D), or expressed for 6 days (6D).  a) HPRT gene expression in mouse heart 
homogenates was examined using qPCR and normalized to reference gene transferrin.  Results 
are expressed as the % change in gene expression relative to WT (n=6).  b) Representative 
Western blot showing HPRT protein expression in mouse heart homogenates (top) and 
quantification of HPRT protein levels in mouse heart homogenates (n=4-7).  * P<0.05 versus 
WT. 
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CHAPTER 7 
 
SUMMARY & FUTURE DIRECTIONS 
 
 These studies showed that HIF-1α expression allows for strong protection of the 
heart during ischemic stress.  We observed that ATP preservation during ischemia in 
our HIF-1α non-induced hearts (Non-I) was not better compared to wildtype hearts, yet 
the Non-I hearts were protected to the same extent as hearts that have been expressing 
HIF-1α for 2 and 6 days.  These results suggest that the ability to preserve ATP is not 
necessarily required to protect the heart from ischemic stress.  Evidence showing that 
many of the protective mechanisms that lead to ischemic tolerance involve the 
protection of the mitochondria is beginning to emerge. 
 
 Here we showed that myocytes isolated from HIF-1α Non-I, 2D, and 6D mouse 
hearts were able to maintain mitochondrial membrane potential better than myocytes 
obtained from wildtype mouse hearts.  Previous studies by our group demonstrated that 
the HIF-1α signaling axis induces the ability for the mitochondria to use purine 
nucleotide cycle derived fumarate as a terminal electron acceptor in place of O2 to 
sustain anaerobic mitochondrial respiration.  In chapter 3 we showed that AMP 
deaminase 2, the entry point to the PNC is upregulated in extracts obtained from 6 day 
HIF-1α expressing hearts as compared to wildtype.  Here we have obtained evidence 
indicating that the protective effects provided by the PNC extends beyond the capability 
to maintain mitochondrial membrane potential during ischemia. 
 
 Treatment of hearts with hadacidin, inhibitor of the PNC at the step of 
adenylosuccinate synthetase followed by ischemia led to a decline in ATP, ATP:ADP, 
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and adenylate energy charge.  Inhibition of ADSS with hadacidin should reduce the 
amount of fumarate available for anaerobic mitochondrial respiration.  This will result in 
the reversal of the F0F1 ATP synthase in order to maintain the inner membrane potential 
of the mitochondria during ischemic stress, which will further deplete ATP.  Thus, in 
addition to sustaining the mitochondrial membrane potential, the PNC also exerts ATP 
sparing effects during ischemia.     
 
 A significant finding in these studies is that HIF-1α limited the adenosine that 
accumulates in the ischemic heart.  While consistent with the shunting of AMP 
metabolism towards the PNC rather than the adenosine producing 5'-nucleotidase 
pathway, we also find that HIF-1α upregulates adenosine deaminase.  Adenosine 
deaminase further degrades adenosine to inosine, thereby contributing to the lower 
adenosine levels that we have observed in the HIF-1α expressing hearts.  Also, we 
were surprised to see that IMP accumulation remained lower in HIF-1α expressing 
hearts as compared to wildtype mouse hearts during ischemia, even though HIF-1α 
upregulates AMP deaminase.  Manfredi and Holmes proposed that some mechanism 
prevents the accumulation of IMP in the ischemic heart.  Taken together, it is likely that 
a multitude of factors determine the instantaneous levels of IMP during ischemia.  Thus, 
we would like to obtain precise quantification of flux through the PNC in the future. 
 
 The observation that HIF-1α limits adenosine accumulation in the ischemic heart 
contradicts the protective function ascribed to adenosine, particularly from the 
perspective of cardioprotection provided by ischemic preconditioning.  However, recent 
evidence has pointed out that chronic adenosine exposure can lead to toxicity.  Future 
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investigations will establish whether HIF-1α can help the ischemic heart avoid 
adenosine toxicity. 
 
 Our studies have also led to the finding that HIF-1α induces the expression of the 
nucleotide salvage enzyme, hypoxanthine phosphoribosyl transferase (HPRT).  HPRT 
catalyzes a reaction that converts hypoxanthine back to IMP.  IMP is then converted 
back to AMP via two reaction steps:  1) IMP to S-AMP by adenylosuccinate synthetase; 
2) S-AMP to AMP by adenylosuccinate lyase.  HPRT may also act in reverse to 
metabolize IMP to hypoxanthine.  While highly speculative, the increased accumulation 
of hypoxanthine during ischemia in HIF-1α expressing versus wildtype hearts maybe 
consistent with the faster rate of IMP metabolism by HPRT.  This provides a plausible 
mechanism that could lead to lower IMP levels in our HIF-1α expressing hearts as 
compared to wildtype during ischemia.  In addition to its role in adenine nucleotide 
salvage, HPRT may also limit the amount of harmful reactive oxygen species (ROS) 
generated during reperfusion.  Future studies will establish that the induction of HPRT in 
HIF-1α expressing hearts allows for better recovery of nucleotides and limits ROS-
induced injury during reperfusion. 
 
 Taken together, we found that HIF-1α expression in the heart provides strong 
protection during ischemic stress.  Further, we identified that HIF-1α induces several 
metabolic pathways that could contribute to cardioprotection.  Future work will aim to 
quantify the flux through these metabolic pathways and to further elucidate the role of 
these pathways in cardioprotection during ischemia. 
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